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Abstract 
 
Site-specific analysis of glycosylated proteins using mass 
spectrometry 
 
By 
 
Janet W Irungu 
 
Doctor of Philosophy in Chemistry 
 
University of Kansas 
 
 
 
Among the numerous post-translational modifications that a protein 
can undergo, glycosylation is by far the most common, having the most 
profound influence on the structural and functional properties of the protein. 
Therefore, profiling glycosylation patterns in glycosylated proteins and 
defining the structures and locations of these glycans is important in 
understanding the structure-function relationship of glycans in glycosylated 
proteins. The work presented herein focuses on applying different mass-
spectrometric methods to profile glycosylation patterns in glycoprotein 
hormones and HIV envelope proteins. To determine the structures and 
locations of the glycans on these proteins, a glycopeptide-based mass 
mapping approach was employed. 
Glycoprotein hormones mainly contain acidic glycans that are highly 
sulfated and/or sialylated. These acidic functional groups affect the biological 
clearance of these proteins. To characterize the glycan structures on 
 
 
iii
glycoprotein hormones, we used a non-specific enzyme to generate small 
glycopeptides that are easier to separate and analyze. However, analysis of 
these glycopeptides can be challenging since it involves simultaneous 
analysis of two unknowns; the peptide and the glycan portions.  
To facilitate identification of the peptide portion, we developed a web-
based tool (GlycoPep ID) that utilizes a characteristic product ion observed in 
(-) MS/MS data of these glycopeptides. To identify the glycan portion, since  
(-) MS/MS analysis gives very minimal glycan structural information; we 
developed an ion-pairing approach, which provides a wealth of structural 
information on the glycan portion of these glycopeptides.  
Finally, an HIV envelope protein, CON-S gp140∆CFI, a potential 
vaccine candidate for HIV/AIDS, was characterized. This protein is 
extensively glycosylated with over 50% of its mass constituting of glycans. 
Although these glycans play a major role in viral defense mechanism against 
the host immune system, the structures and locations of these glycans are 
still not yet known. To develop an efficacious vaccine against this virus, a 
complete characterization of these glycans is required. A full glycosylation 
site-specific analysis of glycans in this protein was performed. This 
information provided biological insights into why CON-S gp140∆CFI is a 
good immunogen, thus a potential candidate for an HIV vaccine.   
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CHAPTER 1 
Introduction 
1.1 Mass spectrometry 
Mass spectrometry (MS) is an analytical technique that is used to 
determine the molecular weight of a molecule. Specifically, MS is used to 
measure the mass-to-charge ratio of a molecule by analyzing its gas phase 
ions. This is typically done by making ions from the sample molecules and 
measuring the mass-to-charge ratio (m/z) of each component present in the 
sample, generating a spectrum that shows the relative abundance of each 
component according to its m/z ratio.1, 2 MS can be used in both qualitative 
and quantitative studies.  
A typical mass spectrometer consists of three basic components; An 
ionization source, a mass analyzer and a detector (See Figure1-1 below). 
The analyte is usually introduced into the ionization source through an inlet 
device, and once in the ion source, ions are generated by inducing loss or 
gain of a charge from the sample molecule. Ions are then transferred into 
the mass analyzer where they are separated according to their m/z ratio 
and counted by the detector.1 
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 Figure 1-1: A block diagram showing the three basic components of 
a mass spectrometer: an ionization source, a mass analyzer, and a 
detector. 
 
 
1.1.1 Ionization sources 
As the name suggests, an ionization source is used to ionize the 
sample molecule thus generating gas phase ions. This is the most 
important part of a mass spectrometer.3 Since the invention of mass 
spectrometry, several ionization sources have been introduced. The most 
common ones include electron ionization (EI), chemical ionization (CI), fast 
atom/ion bombardment (FAB), matrix assisted laser desorption ionization 
(MALDI) and electrospray ionization (ESI). These ionization sources 
function by ionizing the neutral molecule through electron ejection, electron 
capture, protonation, deprotonation, adduct formation, cationization, or 
through the transfer of a charged species from condensed phase to gas-
phase.1, 2  
The mode of ionization selected mainly depends on the 
physicochemical properties of the analyte. For instance, if the analyte is 
volatile and thermally stable, ionization techniques like EI and CI would be 
the most appropriate, since they are very energetic and are more suitable 
for gas-phase ionization. On the contrary, if the sample is non-volatile and 
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thermally labile, softer ionization techniques that are capable of generating 
ions directly from condensed phase to gas-phase ions like MALDI or ESI 
are more appropriate. MALDI and ESI generate gas-phase ions directly 
from solid and liquid phase, respectively. 1, 2, 4 A detailed explanation of how 
ESI works ensues as an example of how these ionization methods work.  A 
description of how each of the other ionization methods work can be found 
in references (1,2,4). 
 
1.1.2 Electrospray Ionization (ESI) 
 The first ESI ionization source was invented in 1989 by John Fenn, 
when he demonstrated the formation of multiply charged ions from large-
molecules, like proteins, which enabled analysis of these molecules with 
mass spectrometers with limited mass range.5 The advent of ESI made 
tremendous contribution in structural analysis of important biomolecules, 
since its evaporation ionization process minimizes dissociation of molecular 
ions during MS experiments. 6-8 ESI ionization technique is the softest 
ionization technique known thus far, and its ability to generate gas phase 
ions directly from liquid phase has also broadened its applicability, since it 
can easily be coupled with separation techniques.9 As a result, ESI is a 
choice method for analysis of wide range of compounds (both small and 
large) and is especially useful during analysis of large nonvolatile 
biomolecules like proteins, oligosaccharides, and glycoproteins. 
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ESI ionization process takes place at atmospheric pressure. Figure 
1-2 shows how this process occurs. As illustrated in this figure, the sample 
solution in a suitable solvent mixture is introduced continuously through a 
capillary tube that is held at a higher potential than the instrument orifice, 
producing a fine spray of highly charged droplets.10 The solvent is then 
evaporated from the charged droplets converting them into gas-phase ions. 
Once formed, these ions are then driven electro-statically towards the 
instrument orifice. The ions are then transported to the high-vacuum mass 
analyzer through a series of pressure-reduction stages. For optimum 
operation, a normal ESI source typically requires flow rates of 2 ─10 uL/min 
and can be operated in the negative or positive ion mode by varying the 
polarity of the voltage applied to the capillary tube. 1, 4, 10, 11 
 
 
4
 Figure 1-2: A schematic representation of ESI process. (Adapted 
from Ikonomou, Blades and Kebarle.)12 
 
1.1.2.1 Mechanism of ESI 
Three different processes are involved in ESI ionization; droplet 
formation, droplet shrinkage, and desorption of gaseous ions.10 When the 
sample liquid flows through the capillary tube that is held at a high voltage 
(2-5 kV), it experiences a strong electric field that causes generation of 
charges through a redox reaction.  For example, if the voltage applied to the 
capillary is positive, an oxidation reaction occurs in solution at the metal 
contact of the sample solution whereas a reduction reaction occurs at the 
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counter electrode. In this case, the continuous removal of negative ions 
from the metal capillary leads to creation of positive ions. This 
electrochemical redox reaction is responsible for facilitating the continuous 
production of charged ions. 4, 10, 12-14 As a result, the positively charged ions 
concentrate at the tip of the capillary and are drawn towards the instrument 
orifice (counter electrode), whereas the anions migrate towards the capillary 
walls away from the tip, as shown in Figure 1-2. Eventually, the liquid 
droplet, populated mainly by positive ions, protrudes from the capillary tip in 
what is known as a “Taylor cone”. When the Coulombic repulsion forces at 
the surface of the liquid droplet exceeds the Rayleigh limit, a point at which 
the Coulombic repulsion forces equals the surface tension of the liquid, the 
liquid droplet explodes into smaller droplets containing an excess of positive 
charges as shown in Figure 1-2.15   
Once the charged droplet is formed, evaporation of the solvent is 
attained through application of heated nitrogen causing the droplet to shrink 
in size. From here, a cascade of ruptures ensues. The charge density on 
the droplet surface increases as it reduces in size (shrinks) and once again 
reaching the Rayleigh limit causing fission of the droplets into smaller highly 
charged droplets. As the solvent evaporation continues, this process occurs 
repeatedly producing smaller and smaller droplets. There are two 
mechanisms that have been proposed to explain how the charged droplets 
produce gas-phase ions, the charge-residue model (CRM) and ion-
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desorption model (IDM). CRM proposes that a series of several solvent 
evaporation and droplet fission occurs repeatedly until a very small droplet 
containing only one solute molecule is formed.4 See Figure 1-3. Eventually 
all the solvent is evaporated resulting in a single molecule that retains the 
charge of the droplet, as shown in Figure 1-3(a) This mechanism is 
attributed to ionization of hydrophilic species. The other mechanism, IDM, 
proposes that as desolvation continues, the electric field on the surface of 
the droplet becomes large enough such that direct emission of single ions 
from the surface occurs. (See Figure 1-3(b)) This mechanism is believed to 
occur in hydrophobic molecules such as peptides and fatty acids.10  
 
 
Figure 1-3: A schematic diagram demonstrating the two mechanisms 
proposed for ESI. The solvent surrounding the molecule is evaporated 
leading to the formation of a charged molecule. (a) Shows the CRM 
mechanism; (b) Represents IDM mechanism. (Adapted from Chhabil Dass.4) 
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1.1.3 Mass analyzers 
Mass analyzers separate ions according their mass-to-charge ratio. 
Different mass analyzers perform this function by separating ions either in 
time or in space. 1, 2 For example, time of flight (TOF) and magnetic sectors 
are spatial mass analyzers, whereas trapping mass analyzers like 
quadrupole ion trap (QIT) and Fourier transform ion cyclotron resonance 
(FTICR) separate ions in time. There are several characteristics of mass 
analyzers that are used to determine their performance. These include 
mass range, accuracy, resolution, MS/MS capabilities, and scan speed.1 
The mass range determines the lowest and the upper m/z that can be 
measured by the mass analyzer. For example, the mass range for TOF is 
theoretically unlimited whereas for a QIT, the mass range is up to m/z 
3000.1 The ability for a mass analyzer to separate different m/z accurately 
and be able to explicitly discriminate them (resolution) also largely 
determines its performance. Among all the mass analyzers currently 
available, FTICR has the highest mass accuracy and resolution capabilities.   
In addition to mass accuracy and resolution, another important feature 
of mass analyzers is their ability to perform tandem mass spectrometry 
experiments.  Tandem mass spectrometry, or MS/MS, refers to the ability of 
the analyzer to isolate a primary ion (precursor ion) in the first MS, activate 
it, fragment it, and analyze the resulting product ions. Mass analyzers that 
separate ions in space are mainly capable of performing one step of these 
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experiments since they are limited to the number of mass analyzers that 
can be combined in series, whereas those analyzers that separate ions in 
time can perform multiple stages of the MS/MS experiments (MSn).2 The 
ability to perform MSn experiments increases the amount of structural 
information that can be obtained thus increasing the applicability of time-
based mass analyzers like FTICR in structural analysis studies of many 
biomolecules.  
Due to the many benefits derived from FTICR, instruments employing 
this mass analyzer have gained wide applicability, not just as a typical 
device that can separate masses based on m/z, but also as a mass 
analyzer that can perform a variety of other unique functions as described 
below.  
 
1.2 Fourier Transform Mass Spectrometry (FTMS) 
FTMS, also known as Fourier transform ion cyclotron resonance 
(FTICR) mass spectrometry, is widely recognized as a mass spectrometer 
with the highest resolution and mass accuracy. The ability to provide exact 
mass measurements and elemental composition assignments is highly 
desirable not only for small molecules, but also large biomolecules. Virtually 
any ionization technique can be coupled to FTICR, which increases its 
applicability. For example, the simultaneous implementation of both ESI 
and MALDI, the two most useful ionization methods for oligosaccharide 
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analysis was first performed by FTICR.16 The ability to couple FTICR with 
ESI also allows the analysis of very large molecules through the formation 
of multiply charged ions with high isotopic resolution, thus increasing the 
upper mass limit for FTICR MS.6, 17 This instrument also provides additional 
benefits like simultaneous detection of all ions in non-destructive manner 
making it ideal for analysis of minute quantities of samples.18 The timescale 
(milliseconds to hours) for FTICR also makes it a versatile instrument that 
can be used to perform various experiments like slow (and fast) ion-
molecule reaction experiments, collision induced dissociation (CID) 
experiments, photo-dissociation etc.19 All these benefits collectively make 
FTICR a very powerful instrument for providing both molecular weight 
measurements and for structural elucidation studies. 
 
1.2.1 Instrumentation 
Since its innovation in 1974 by Comisarow and Marshall, FTICR has 
undergone a tremendous transformation.20 Currently, there are various 
designs of FTICR that are commercially available, but regardless of the 
design, all FTICR share several common features which include a magnet, 
an analyzer cell, an ultrahigh vacuum system, and a data system.18, 21 The 
best performance for FTICR is achieved with high magnetic field strength 
and very low pressure.22, 23 However, the heart of this instrument is the 
analyzer cell, which is an ion trap that can act as an ion source, mass 
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analyzer, and detector, where ions are always separated in time rather than 
in space.18, 24 Because of the pressure differences between an ionization 
source and a mass analyzer, most FTICR instruments are designed with an 
external ion source separated spatially from the high vacuum of the mass 
analyzer cell.17, 22 The mass analyzer cell is housed inside a large magnet 
and can either be cubic or cylindrical in shape. The most common geometry 
is a cubic cell containing three pairs of electrodes classified as follows; two 
trapping plates (front and back electrodes), two excitation plates (the side 
electrodes), and the two detector plates (the top and bottom electrodes).18, 
21, 24-26 See Figure 1-4. Ions are injected into the analyzer cell along the 
same direction as the magnetic field lines and they are confined to the 
center of the cell by application of a small voltage on the trapping plates. 
The trapped ions can then be manipulated and ultimately detected based 
on their interactions with the magnetic and electric fields present in the 
mass analyzer cell.  
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 Figure 1-4: Diagram representing FTICR instrument. The mass analyzer 
comprises of three types of plates, labeled as trapping, excitation and 
detector plates. Ions enter the ICR cell along the z-direction and rotate 
along the x-y plane as shown above, inducing an image current that is 
detected and fourier transformed to give a mass spectrum. (Adapted from 
http://www.chm.bris.ac.uk/ms/theory/fticr-massspec.html, 11/10/07) 
 
1.2.2 General principle of Ion cyclotron resonance (ICR) 
An ion of charge (q) and mass (m) travelling at velocity (v) through a 
uniform static magnetic field (B) experiences a force (F) that is 
perpendicular to its velocity, causing its motion to curve or rotate 
perpendicular to the magnetic field direction.25, 27-29 See Figure 1-5 below. 
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Figure 1-5: Shows the motion of the ion in a magnetic field. The polarity of 
the ions determines the direction of motion. Figure on the left shows the 
motion of a positively charged ion and the one on the right indicate the 
direction of a negatively charged ion in a static magnetic field. (Adapted from 
Marshall et al.29) 
 
 
 This force (Fin), also called Lorentz force is balanced by an outward 
centrifugal force (Fout) stabilizing the ion along its cyclotron path.2, 30 See 
Figure 1-5 above. This can be described by the following basic equations. 
 qv * B =   
mv2
   r 
          Inward Lorentz force  = Outward force 
         (Equation 1) 
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Where r is the orbital radius of the ion’s motion in the magnetic field. The 
cyclotron or rotational frequency of the ion can be obtained by rearranging 
the above equations as follows. 
            (Equation 2) 
v
 r 
 qB 
  m = 
Where v/r represents the cyclotron frequency, ωc, in 2πx (cycles per 
second), B in Telsa, m in kilograms, r in meters, q in Coulombs, and v in 
meters per second.25, 28, 30 As shown from equation 2, the cyclotron 
frequency is inversely proportional to the mass-to-charge ratio (m/q or m/z). 
All ions of the same m/q rotate at the same cyclotron frequency, 
independent of their velocity.30 Therefore, the mass-to-charge ratio of an ion 
is determined by measuring its cyclotron frequency. This is the most 
notable and unique advantage of FTICR, since frequency can be measured 
with high precision.22, 27 As a result, this technique offers the highest mass 
resolution and mass accuracy compared to other types of mass 
measurements.30, 31  
 
1.2.3 Ion injection into ICR  
Although there are some ionization techniques like EI that can easily 
be implemented inside the ICR analyzer cell, it is more beneficial to have 
the ionization source outside the large magnetic field.18, 28, 32 Furthermore, 
generating ions from nonvolatile molecules can be a daunting task when 
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performed inside the magnet.18, 24  As a result, ions are typically generated 
by an ionization source located outside the analyzer cell. Several differential 
pumping stages are placed between the ionization source and the analyzer 
cell to decouple high pressures of the ion source from the ultra low 
pressures of the ICR mass analyzer (10-9 Torr or less).18, 24, 30, 33, 34 
However, injecting ions into the analyzer cell is a major hurdle since the 
ions not only have to penetrate through the large magnetic field, but they 
also have to slow down in order to be trapped inside the analyzer cell.30, 34 
Typically, ions enter the analyzer cell through a small opening on the 
front trapping plate along the z direction or the magnetic field direction (See 
Figure 1-4) To allow ions to enter the analyzer cell, the voltage of the front 
trapping plate is lowered while the one on the back trapping plate is 
increased to prevent the ions from exiting the analyzer cell.34 The potential 
of the front trapping plate can then be raised to prohibit ions from returning 
to the front trapping plate and this also prevents more ions from entering 
the ion trap (analyzer cell).30, 34 To trap ions of a particular m/q (q is the 
same as z in the term m/z), the potential applied to the trapping plates is 
usually varied to optimize the trapping of those ions.35 Alternatively, once 
the ions enter the cell, their kinetic energy can be lowered through 
collisional dampening with a background gas thus slowing them down and 
permitting them to be trapped. This allows ions to be accumulated for 
longer periods.36  
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 1.2.4 Ion trapping in the ICR 
Once inside the cell, ions are constrained in the analyzer cell or ion 
trap by a combination of two forces, electrical and magnetic forces. The 
main constraining force comes from the magnetic field which “traps” the 
ions by directing their path in a circular motion away from the analyzer cell 
walls. This traps the ions in two-dimensions, the x-y plane which is 
perpendicular to the magnetic field as shown in Figure 1-4. The magnetic 
field is parallel to the z-axis of the analyzer cell (trap). This field is fixed 
such that each m/q has a unique cyclotron frequency as described by 
equation 2. However, this cyclotron equation does not account for the force 
that constrains the ions in the axial z-direction.24, 25, 30, 34 To prevent the ions 
from escaping along the z-direction, thus trapping them in the third 
dimension, an electric field is employed.   This is done by applying a small 
voltage (about 1V), of the same polarity as the ions of interest to the 
trapping plates (both front and back).18, 21 By combining the contributions of 
the magnetic and electric fields, ions orbit with a cyclotron frequency, ωc, 
that varies with both magnetic (B) and electric (E0) field strengths as 
defined by the following equation. 
     (Equation 3) 
ωc = qB + ( q2B2 – 4mqEo)1/2
     2m 
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 In the absence of electric field (E0), equation 3 is equal to equation 2. For 
further explanation on the basis for this equation, see references (25, 26, 31, 
and 38) 
Other forces that contribute to the outward electric fields include space 
charge effects. These forces are due to Coulombic repulsion forces 
between the ions in the trap. The magnitude of these forces increases as 
the number of ions accumulated in the trap increases. However, the effect 
of these forces is not as much as the one resulting from the trapping 
potential.24 
 
1.2.5 Ions excitation and detection in FTICR 
Before excitation, the trapped ions move in small cyclotron orbits 
along or near the z-axis at different cyclotron frequencies depending on 
their m/z ratio. For instance, ions of the same m/z rotate at the same 
frequency but occupy different positions about the circular orbit therefore 
out of phase.24, 29 To excite these ions and ultimately detect them, the 
remaining four plates parallel to the magnetic field are utilized. The 
excitation process involves the application of a range of radio frequencies 
(RF) that are in resonance with the ions’ cyclotron frequencies to the two 
excitation plates (see Figure 1-4). Consequently, the ions absorb energy, 
causing their cyclotron radius to enlarge and become coherent (in-phase); 
thus, ions of the same m/z follow a coherent orbital path, with the same 
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radius. If the applied RF voltage is sufficiently high, ions will end up hitting 
the plates, and they are lost. This method can be used to eject unwanted 
ions, leaving the ions of interest for further experiments. For detection, the 
RF is usually turned off before ions can strike the cell plates.18, 24 
To detect the ions, an image current that is induced by the ions as 
they pass by the two detector plates (top and bottom electrodes) is 
measured. The induced current oscillates at the same frequency as the 
coherently moving ions, which in turn depends on their m/z values. This 
current is then detected in an external circuit between the two detection 
plates. This current is referred to as the image current and is detected as a 
function of time. Since the ions are not destroyed, they can be re-
measured, thus increasing the sensitivity and resolution of this instrument. 
The current is then amplified, and Fourier transformed from the time-
domain to the frequency domain, generating a mass spectrum as shown in 
Figure 1-4.  
 
1.3 MS/MS experiments  
MS/MS experiments, also known as tandem MS, involves separating 
or isolating the ion of interest (precursor ion) in the first MS, which is then 
followed by activation and fragmentation of that ion to produce its product 
ions. Fragmentation of the precursor ion is usually achieved by colliding the 
ion it with inert gas molecules. The fragmentation/product ions are then 
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collectively used to provide structural information of the precursor ion. As 
previously mentioned (see section 1.1.3), the ability to perform MS/MS 
experiments depends on the instrument (mass analyzer) employed. FTICR 
is one of the few instruments capable of performing MSn experiments, 
which are extremely useful for structural elucidation of complex molecules 
like glycoproteins and oligosaccharides. In addition, FTICR gives the best 
isotopic resolution for multiply charged ions making it possible to interpret 
mass spectral data for large molecules ionized by ESI.16, 37 
 
 1.3.1 MSn experiments in ICR cells 
Once ions are trapped inside an FTICR mass analyzer cell, a 
precursor ion can be selected for further experiments. The excitation 
process described previously can be used to eject all unwanted ions from 
the analyzer cell by causing them to collide with the cell plates. After the ion 
of interest, or precursor ion, is isolated, various methods can be utilized to 
activate the precursor ion to promote collision induced dissociate (CID). 
Sustained off-resonance irradiation (SORI) is the most commonly used 
method for activation. In this case the precursor ion is excited at a 
frequency that is slightly off-resonance causing the ion to be in and out of 
phase. As a result, the ion is excited and de-excited alternately. A pulsed 
collision gas is then introduced into the cell when the ions are off-resonance 
excitation.18, 21 The low energy collisions are sustained and eventually the 
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precursor ion gains enough energy to cause it to dissociate. This method is 
more efficient and selective than other modes of excitation, including on 
resonance excitation and stored waveform inverse Fourier transform 
(SWIFT) excitation. A description of the fundamentals of the other excitation 
methods is provided by Marshall and co-workers.21, 27, 38 
 Other types of MS/MS experiments that can be performed in FTICR 
include photo-dissociation of large molecules. These include multi-photon 
infrared photo-dissociation (IRMPD) where infrared (IR) laser photons are 
employed to slowly heat the molecules thus producing low-energy 
fragments similar to CID.39 IRMPD differs from CID in that unlike CID, it 
does not require the use of gas pulses hence the dissociated ions can be 
detected at high resolution as they form. 40 Alternatively, blackbody infrared 
radiative dissociation (BIRD) can be employed whereby a thermally heated 
ICR cell is utilized.41 Another MS/MS technique that can be performed in 
FTICR is electron-capture dissociation (ECD), which involves exposing 
multiply charged cations trapped in ICR cells to low-energy electrons.17, 42  
 
1.4 The role of mass spectrometry in glycosylated proteins analysis 
Mass spectrometry (MS) is one of the most versatile analytical 
techniques that has gained widespread use in glycosylated protein analysis, 
due to its high selectivity and sensitivity and the ability to analyze complex 
mixtures rapidly. The advent of soft ionization techniques such as fast atom 
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bombardment (FAB), electrospray ionization (ESI)5 and matrix assisted 
laser desorption ionization (MALDI)43 revolutionized many research fields 
by providing new insights into the structural details on many levels for 
various important classes of biomolecules. One of those fields, which has 
benefited tremendously from MS is the glycoproteomics field. New 
inventions in MS continue to make enormous contribution in this field. 
Glycoprotein analysis by MS is typically achieved by two main 
approaches labeled as (1) and (2) on the schematic diagram below (Figure 
1-6). In approach (1), the glycoprotein is proteolytically digested resulting to 
a mixture of peptides and glycopeptides, while approach (2) involves 
cleaving off the glycans from the protein backbone either enzymatically or 
chemically producing a mixture of peptides and glycans. In both 
approaches, a separation step is required to remove the peptides prior to 
MS analysis. Approach (1) is more advantageous than approach (2) since it 
does not require extra sample manipulation like derivatization,44 and allows 
site-specific glycosylation profiling.45  
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 Figure 1-6: A schematic diagram illustrating the two main approaches used 
in glycosylated proteins analysis by MS. Approach (1) uses either trypsin 
(specific) or proteinase K (non-specific) enzyme to produce a mixture of 
peptides and glycopeptides. Approach (2) employs PNGase F (an enzyme 
that cleaves off N-linked glycans) or chemicals like hydrazine to cleave off 
the glycans from the protein resulting in a mixture of glycans and peptides.  
 
 
1.5 Glycosylated proteins 
Glycosylated proteins, or glycoproteins, are proteins to which 
carbohydrates moieties are covalently attached through glycosidic bonds. 
This process is known as glycosylation and is the most ubiquitous 
modification that occurs on cellular and secreted proteins.46-48 Although very 
common, glycosylation is a highly specific process and mainly occurs on 
three amino acids residues; asparagines (Asn), serine (Ser), and 
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threonine(Thr). There are only two ways glycans can be attached to these 
amino acid residues; through the amide nitrogen of Asn forming the N-
glycosidic bond; or through the hydroxyl oxygen of Ser or Thr forming the 
O-glycosidic bond, hence the N- and O-glycosylation types, respectively. N-
glycosylation is the most common type of glycosylation in eukaryotic cells 
and some prokaryotic cells, and is therefore the focus of the studies 
presented herein.49, 50 
 
1.5.1 Biosynthesis of N-glycosylated proteins 
 The process by which proteins are N-glycosylated in mammalian 
systems is highly complex and follows a series of pathways. This process 
occurs both co- and post-translationally in proteins bearing an asparagine in 
a consensus sequence of tripeptide Asn-Xaa-Ser/Thr, where X can be any 
amino acid except for proline, thus each of these tripeptide sequences 
constitute a potential glycosylation site.50 N-glycosylation starts when a 
preformed precursor oligosaccharide (Glc3Man9GlcNAc2) attached on a 
carrier lipid is transferred to a nascent protein chain (containing the Asn-
Xaa-Ser/Thr sequon) in the endoplasmic recticulum (ER) as shown in 
Figure 1-7. As the nascent protein chain continues to grow, several 
subsequent reactions occur that are catalyzed by enzymes, (“modifying 
enzymes 1” shown in Figure 1-7) specifically, glucosidases and 
mannosidases present in the ER, leading to the precursor oligosaccharide 
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being trimmed down to a high-mannose N-linked glycan. Further trimming 
and processing of the precursor oligosaccharide may take place as the 
protein migrates to the Golgi apparatus (GA) where it encounters various 
processing enzymes (galactosyl, sialyl, fucosyl transferases, GlcNAc and 
GalNAc transferases – “modifying enzymes 2” shown in Figure 1-7) to 
produce hybrid and complex type of N-linked glycans.49 This results in N-
linked glycans that are highly heterogeneous, particularly in the terminal 
residues. Thus, structural diversification of N-linked glycans occurs in the 
GA where the N-linked glycans are transformed from high-mannose sugars 
into a large, diverse repertoire of hybrid and complex N-linked glycan types 
that are then secreted and presented on the cell surface as glycosylated 
proteins as illustrated in Figure 1-7 below.49, 51  
 
Figure 1-7: Biosynthesis of N-glycosylated proteins. The nascent protein is 
glycosylated as it grows and this process starts in the ER and ends in the 
GA after which the glycosylated protein is presented on the cell surface. 
The structures shown after modifying enzymes arrows represent one of the 
many possible examples of what the glycans could be. 
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 As a result, the secreted glycosylated protein contains a diverse population 
of glycoforms that may consist of one to several different types of N-linked 
glycans attached at the same or different glycosylation site(s). The end 
result is a glycosylated protein that is structurally complicated hence very 
challenging to characterize. This is one of the main reasons why the 
glycoproteomics field has been lagging behind the field of proteomics. 
As shown in Figure 1-8, all N-linked glycans have a common 
pentasaccharide (triamannosyl) core and only vary based on the type and 
number of sugars added and how they are branched from the triamannosyl 
core. Depending on substitution of the non-reducing terminal residues in 
this core structure, the N-linked glycans can be classified as complex, high-
mannose, and hybrid type as shown in Figure 1-8. The high-mannose type 
contain the most number of mannose residues, while the hybrid and 
complex types are often processed further by addition of terminal residues 
like sialic acid or sulfate, and sometimes contain a fucose linked to GlcNAc-
Asn.  
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 Figure 1-8: Types of N-linked glycans.  All N-linked glycans start from the 
precursor oligosaccharide which is then trimmed down to a) high-mannose, 
b) Hybrid, and, c) Complex type. The broken arrow indicates the building 
block for all N-linked glycans. (also boxed pentasaccharide core)  
 
 
1.5.2 Factors affecting biosynthesis of N-glycosylated proteins 
The biosynthesis of N-glycosylation in proteins is a highly specific 
process that depends on the specific cell type expressing the protein, the 
specific polypeptide chain of the protein to be glycosylated (which usually 
contains encoded information that directs its glycosylation) and the specific 
glycosylation site to be glycosylated.49, 51 Other factors that affect protein N-
glycosylation include protein conformation which may affect the accessibility 
of potential glycosylation sites to modifying enzymes, transport rates in 
endoplasmic recticulum (ER) and Golgi, cellular regulators that affect 
glycosyl-transferases’ activity, and localization of glycosyltransferases 
 
 
26
(availability of modifying enzymes and the order in which they interact with 
the protein).49, 51 All these factors also contribute to structural diversification 
of N-linked glycans.  
 
1.5.3 Biological Importance of N-linked glycosylated proteins 
 In humans, approximately 50-60% of all the proteins are 
glycosylated.52, 53 The glycan content in these proteins accounts for about 
4-60% of the total protein mass. The presence of these glycans in proteins 
is known to have profound influence on the physiochemical, cellular and 
biological functional properties of proteins. For instance, glycans play key 
roles in physiochemical properties of proteins such as stability, folding, 
conformation, solubility, and protecting proteins against proteolysis.54 In 
addition, glycans also influence biological processes in proteins like 
facilitating cell-cell recognition, recognition of hormones, toxins, viruses, 
coordination of immune functions; glycans are also involved embryonic 
protein-glycan interaction.55-58 In addition, variations in glycan structures 
have been observed in several pathological states such as cancers, 
rheumatoid arthritis, carbohydrate-deficient glycoprotein syndromes 
(CDGS).49 So far, there are several glycoproteins that have or are being 
investigated in biomedical research for disease prognosis and for 
therapeutic purposes.  For instance, about 25% of the currently approved 
cancer biomarkers are glycosylated proteins.59 Consequently, defining the 
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structures and locations of these glycans in proteins may provide useful 
insights into how variation in glycosylation affects the functions of proteins 
in health and disease thus provide valuable information that can be useful 
in facilitating the understanding of structure-function relationship. In order to 
acquire this information, sensitive, rapid and reliable methods for mapping 
and profiling glycosylation in proteins are required. 
 
1.6 An overview and summary of the following chapters 
The work presented herein focuses on developing mass spectrometric 
methods to characterize glycans in different glycoproteins in a glycosylation 
site-specific fashion. This approach allows structural elucidation of both the 
glycan and their attachment site in a single-MS experiment. Characterizing 
the glycans in glycoproteins in a glycosylation site-specific manner is 
important because the functional role of the similar glycans structures varies 
from protein to protein as there is no general function that can be attributed 
to similar glycans in different proteins or different glycans in the same 
protein.60 In order to understand the structure-function relationship of glycans 
in glycoproteins, structural analysis is important. As a result, it is critically 
important to not only characterize glycans but also determine their precise 
locations on each protein. The studies described herein, mainly focused on 
two important classes of glycoproteins: glycoproteins hormones and 
glycoproteins found on the surface of a virus such as HIV envelope proteins. 
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The main interest in characterizing glycans in glycoprotein hormones and 
HIV envelope proteins stems from their biological significance.  
The glycoprotein hormones analyzed here are from a family of 
heterodimeric glycoproteins that consist a non-convalently linked alpha and 
beta subunit.61 They consist of luteinizing hormones (LH), thyroid stimulating 
hormone (TSH), follicle stimulating hormone (FSH), and chorionic 
gonadotropin (CG). LH, FSH, and TSH are all secreted from the anterior 
pituitary gland whereas CG is secreted from the placenta.62 The pituitary 
hormones are involved in regulating reproductive and metabolic functions in 
the body.58, 61, 63 Structural studies on these hormones indicate that glycans 
account for 15-35% of the total molecular weight of these hormones. These 
glycans contain unusually high content of terminal acidic residues such as 
sulfate groups and sialic acid.64 For example, TSH contains glycans that are 
exclusively sulfated while the FSH contains glycans that are both sialylated 
and sulfated. These terminal residues act as unique features on these 
glycans that are recognized by specific receptors. For instance, glycans 
capped with a sulfate group are recognized by a receptor in the liver, 
facilitating their plasma clearance.65 Therefore, the addition of a sulfate group 
targets these hormones for rapid removal from the body. In addition, the 
presence of these terminal residues have been associated with several 
diseases such as cancer, rhemautoid arthiritis etc.49 However, the precise 
differences in degree of sulfation or sialylation between healthy and infected 
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individuals and the role that these residues play are still not well understood. 
This is mainly due to the acidity and lability of these groups, creating a 
significant analytical challenge that has greatly hindered the analysis of these 
species.  We have developed and validated MS methodologies for 
characterizing glycans containing these terminal residues in a glycosylation 
site-specific manner and successfully applied them in characterizing 
glycoprotein hormones.66 These MS methods are not only applicable to 
glycoprotein hormones but can also be applied to any glycoprotein containing 
these terminal residues.  
The other class of glycoproteins that we have characterized are 
glycoproteins found on the surface of HIV virus. HIV virus is a retrovirus that 
causes acquired immune deficiency syndrome (AIDS), which has lead to a 
world epidemic that is claiming millions of human lives every year.67, 68 The 
entry and fusion of this virus to its target host cells is mediated by an 
envelope glycoprotein, gp160, which consists of an exterior envelope protein 
(gp120), anchored onto the viral membrane by a trans-membrane envelope 
protein (gp41).69-71 The exterior surface envelope, gp120, is exposed to the 
immune system of the host cells and is therefore the main focus for HIV 
vaccine development. 68, 72 This envelope protein is one of the most 
glycosylated proteins known in nature, with over 50% of its mass consisting 
of glycans.73, 74 It has been suggested that the high population and diverse 
range of glycan structures on this protein act as a shield for the virus and 
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protect it from proteolytic degradation.74, 75 In addition, these glycans act as 
the major defense mechanism for the virus by masking the underlying 
epitopes on the protein backbone making them invisible to the immune 
system.75-81 The glycan shield is also said to evolve during infection and 
throughout the HIV disease progression, and this evolution can result in 
changes in glycan structures, position, and/or number of glycosylation 
sites.78, 81-86 As a result, mapping the glycosylation sites on HIV envelope 
proteins, determining the structures, populations, and location of these 
glycans on the protein is important and may yield valuable information that 
may contribute in developing the long anticipated HIV vaccine. Unfortunately 
glycoprotein analysis is generally a very challenging task44, 87, 88 and among 
all the N-linked glycoproteins that have been studied so far, gp120 envelope 
protein is by far the most complicated. This is due to its protein sequence 
variation and the high number of potential glycosylation sites (over 24 
potential glycosylation sites), each containing a high population of a wide 
range of glycan structures that can evolve with time,73, 81, 89-94 therefore 
posing a great challenge to most analytical methods that are currently 
available. We have developed different MS techniques to characterize N-
glycans of one of the potential candidates for an HIV vaccine, CON-S 
gp140∆CFI, which is derived from gp160, in a glycosylation site-specific 
manner.  By employing these strategies, we have successfully characterized 
hundreds of N-glycans, and detected all the 31 potential glycosylation sites 
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present in this protein. The glycan profiles of this vaccine candidate can be 
correlated to immunogenicity, as a first step in using glycosylation 
information to aid vaccine development. 
 
Chapter 2 
A new approach to characterize sulfated glycans present on 
glycoproteins is described.  The analysis is performed on glycopeptides, so 
information about the sulfated species was obtained in a glycosylation site-
specific manner. Typically, negative ion mode is the method of choice for 
analysis of sulfated glycans since negatively charged species ionize more 
efficiently in the negative ion mode. However, (-) MS/MS for sulfated 
glycopeptides provides limited structural information due to the lability of the 
SO3 group. To overcome this problem, a method that employs an ion-pairing 
reagent to stabilize the SO3 group of the glycopeptides was developed 
thereby promoting other dissociation pathways that provide more structural 
information. The amount of structural information obtained from (+) ESI-
MS/MS of the ion-pair complexes for sulfated glycopeptides of equine thyroid 
stimulating hormone (eTSH) was compared with information obtained by (-) 
ESI-MS/MS of the un-derivatized, sulfated glycopeptides. The results 
indicated that this new method provides detailed insights into the sequence, 
branching and type of N-glycans present, compared to analysis via (-) ESI-
MS/MS.66   
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 Chapter 3 
Mass spectral analysis is an increasingly common method used to 
characterize glycoproteins.  When more than one glycosylation site is 
present on a protein, obtaining MS data of glycopeptides is a highly effective 
way of obtaining glycosylation information, because this approach can be 
used not only to identify what the carbohydrates are, but also at which 
glycosylation site they are attached.  Unfortunately, this is not yet a routine 
analytical approach, in part because data analysis can be quite challenging.   
We have developed strategies to simplify this analysis. Presented herein is a 
novel mass spectrometry technique that identifies the peptide moiety of 
either sulfated, sialylated or both sialylated and sulfated glycopeptides. This 
technique correlates product ions in collision induced dissociation (CID) 
experiments of suspected glycopeptides to a peptide composition, using a 
newly developed web-based tool, GlycoPep ID.  After identifying the peptide 
portion of glycopeptides with GlycoPep ID, the process of assigning the rest 
of the glycopeptide composition to the MS data is greatly facilitated because 
the “unknown” portion of the mass assignment that remains can be directly 
attributed to the carbohydrate component.  Several examples of the utility 
and reliability of this method are presented herein.95   
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Chapter 4 
CON-S gp140∆CFI is a potential candidate for HIV/AIDS vaccine and 
to our knowledge, it is the most N-glycosylated protein characterized so far, 
with 31 potential glycosylation sites. While the protein sequence of this 
protein is well known, the glycans shielding its surface, which accounts for 
about 50% of its molecular weight, have not yet been characterized. 
Furthermore, although mass spectrometry has gained a widespread use in 
glycoprotein analysis, so far there is no consensus as to which mass 
spectrometry method gives the best glycosylation coverage. As a result, to 
characterize this important protein, the two most widely used MS techniques, 
LC/ESI-MS and MALDI-MS were employed and the results obtained 
therewith compared to determine which of the two techniques would be more 
suitable for analysis of a complicated glycoprotein like CON-S gp140∆CFI in 
providing the most glycosylation information content in this protein in terms of 
sequence coverage, number and type of glycans.  
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CHAPTER 2 
 
A Method for Characterizing Sulfated Glycoproteins in a Glycosylation 
Site-Specific Fashion, Using Ion-Pairing and Tandem Mass 
Spectrometry   
 
Reprinted by permission from Anal Chem 2006, 78, 1181-1190. Copyright 
2006 American Chemical Society. 
 
2.1 Introduction 
Glycoproteins bearing sulfated carbohydrates have been identified 
from different species, ranging from bacteria to humans.1-3 Changes in 
sulfation have been linked to osteoarthritis,4-6 cystic fibrosis, and cancer.7-9 
Glycoprotein hormones, particularly lutropin (LH) and thyrotropin (TSH), are 
heavily sulfated hormones that regulate reproduction and metabolism.1,10,12 
These hormones consist of two non-covalently linked α and β subunits, each 
containing one to two glycosylation sites. The degree of sulfation at each of 
these sites varies significantly within a given hormone. For example the 
single glycosylation site at the β subunit in lutropin contains the greatest 
proportion of disulfated glycans, whereas one of the two sites on the α 
subunit contains the greatest percentage of monosulfated glycans.10-13 The 
presence of the sulfate groups in these hormones can alter their biological 
recognition and facilitate their rapid clearance from the body.14 As a result, 
studying sulfation at each of these sites is important to understand how the 
carbohydrate structure affects the function of these hormones.  To date, an 
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analytical method is not available that can both identify sulfation in a 
glycosylation site-specific fashion, and characterize the sulfated glycans.  
Therefore, developing efficient and sensitive analytical techniques that are 
capable of identifying and characterizing sulfated species in a glycosylation 
site-specific manner are needed, in order to facilitate the understanding of 
their biological significance.  
One of the most common biochemical methods to identify sulfated 
glycans is metabolic radiolabeling, followed by fractionation and 
characterization of the resulting glycans.9-11,13,15-18 This method has the 
advantage of distinguishing the presence of isomeric structures, which can 
be very useful for structural elucidation. Although highly effective, this 
approach can be hazardous and time consuming. Most often, glycans are 
released from the protein using chemical or enzymatic procedures. As a 
result, information is not available about which glycans originated from which 
glycosylation sites, unless the glycosylation sites are separated before 
glycan release.  
Mass spectrometry (MS) has emerged as an important analytical tool 
in the structural elucidation of glycoconjugates. It has the advantage of high 
sensitivity, speed, and low sample requirements.19 Typically, MS analysis of 
glycoproteins is done after the glycans are released from the polypeptide 
backbone.20 This technique has been previously applied to analyze sulfated 
glycans using fast atom bombardment (FAB),21 electrospray ionization 
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(ESI),3 and matrix assisted laser desorption-ionization (MALDI).22 While this 
method is highly effective, it fails to provide glycosylation site-specific 
information that is essential in understanding structure/function relationship 
of glycans in glycoproteins. 
An alternative approach, which has the advantage of providing site 
specific information, involves proteolytic digestion of the glycoprotein 
followed by MS analysis of the resulting glycopeptides.20,23-26 Unfortunately 
the applicability of this strategy in the analysis of sulfated glycopeptides is 
limited because proteolysis liberates both sulfated and non-sulfated 
glycoforms, and the signal of the sulfated gycopeptides is suppressed in both 
positive and negative ion mode during MS analysis.24 To overcome this 
limitation, an MS strategy that employs an ion-pairing reagent to enhance the 
signal of sulfated glycoforms has been recently developed.24
In addition to signal suppression, another challenge that has lead to 
the limited applicability of direct mass spectrometric analysis of sulfated 
glycopeptides is the fact that MS/MS data of sulfated glycopeptides are very 
different than MS/MS data acquired from related species, including 
nonsulfated glycopeptides and sulfated glycans.24  It is well known that 
sulfated species ionize better in the negative ion mode; however, preliminary 
studies of (-)ESI-MS/MS spectra of sulfated glycopeptides indicate that very 
minimal structural information is obtained.24  This may be attributed to the 
fact that dissociation pathways in the negative ion mode are driven by the 
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deprotonation site.  Since the site of deprotonation is not on the carbohydrate 
backbone, glycosidic cleavages, which would provide structural information 
about the carbohydrate, are not readily observed.24 Thus, structural 
characterization of sulfated glycopeptides using traditional methods is not a 
straightforward task.  
Herein we demonstrate that by using an ion-pairing reagent, sulfated 
glycopeptides can be analyzed in positive ion mode, and significant structural 
information is obtained during MS/MS analysis.  While ion-pairing has been 
used previously to enhance the MS signal of sulfated compounds24, 27-30, and 
to discriminate sulfation from phosphorylation,31 this is the first report that 
demonstrates MS/MS of the ion-pair complexes provides structural 
information for the complexed analytes.  In this report, sulfated glycopeptides 
from horse TSH, possessing glycan structures identical to those 
characterized in bovine and human TSH,11,22 were subjected to MS/MS 
analysis in both negative ion mode (without ion-pairing reagent) and in 
positive ion mode, after the addition of the ion-pairing reagent.  The 
information obtained from the two MS/MS techniques is described.  To 
demonstrate the general applicability of these studies, the fragmentation 
trends that are described for (-) ESI-MS/MS and ion-pairing MS/MS were 
used to characterize the structures of two unknown, sulfated glycopeptides.   
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2.2 Experimental  
2.2.1 Digestion of eTSH with Proteinase K 
Glycopeptides from equine thyroid stimulating hormone (eTSH) were 
generated in the laboratory of Dr. George Bousfield, Wichita State University.  
Briefly, the eTSH glycoprotein was reduced and alkylated based on a method 
described previously.32  The glycoprotein was desalted using centrifugal 
ultrafiltration, digested with proteinase K (10%w/w) and dried.25 The eTSH 
digests were then subjected to Superdex peptide gel filtration 
chromatography.  The fraction containing carbohydrates was collected, dried, 
and analyzed as described below. 
2.2.2 Peptide Sequencing (Edman) 
The peptide sequences of these glycopeptides were verified by 
automated Edman degradation using an Applied Biosystems (Foster City, 
CA) model 492 Procise sequencer.  The eTSH digests were applied to 
Biobrene-coated glass fiber membranes that had been precycled in the 
sequencer. Typical sequencer experiments consisted of seven automated 
Edman degradation cycles, sufficient to sequence the entire length of 3-5 
residue peptides resulting from proteinase K digestion. 
2.2.3 eTSH glycopeptide preparation for MS analysis 
The dried glycopeptides were first dissolved in water and diluted with 
MeOH:H2O (4:1) containing 0.3% acetic acid, to constitute a final 
concentration of 0.03 μg/μL.  This solution was used directly for (-) ESI-MS 
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analysis.  It was also used in the ion-pairing experiments.  For ion pairing, a 
tripeptide (Lys-Lys-Lys or 3K), purchased from Sigma-Aldrich (St. Louis, 
MO), was first dissolved in H2O and diluted to 0.1 μg/μL MeOH:H2O (4:1) 
containing 0.3% acetic acid. Ion-pair complexes were formed by combining 
equal volumes of the basic peptide and the glycopeptide solutions. The 
mixture was vortexed prior to injecting into the mass spectrometer. 
2.2.4 Mass Spectrometry 
MS data was acquired on a high-resolution Thermo Finnigan linear ion 
trap-Fourier Transform Ion Cyclotron Resonance mass spectrometer, LTQ-
FTICR, (San Jose, CA) equipped with a 7 Telsa actively shielded magnet. 
Samples were directly infused into the mass spectrometer using a syringe 
pump at a flow rate of 5 μL/min.  High resolution data was acquired by 
maintaining resolution at 50,000, for m/z 400. The instrument was externally 
calibrated prior to the analysis, over the entire mass range of interest. The 
data was acquired in the mass range of m/z 800-2000.  Electrospray 
ionization in negative mode was achieved using a spray voltage of 
approximately -4.0 kV. N2 was used as a nebulizing gas at 20 psi, and the 
capillary temperature was maintained between 200-230 oC. Data was 
acquired and processed using Xcalibur 1.4 SR1 software (Thermo Finnigan 
San Jose, CA).  The glycopeptide compositions were assigned for the peaks 
in the high resolution data by using a visual basic algorithm, developed 
previously.25  
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Data was also acquired in the positive ion mode after the addition of 
an ion-pairing reagent. Electrospray ionization in positive mode was achieved 
using a spray voltage of 4.0 kV.  All ions that corresponded to ion-pair 
complexes of the ions observed in (-) ESI-MS were subjected to (+) ESI-
MS/MS. 
2.2.5 MS/MS analysis 
MS/MS experiments were performed using the linear ion trap mass 
analyzer, on the LTQ-FTICR MS, to confirm the assigned glycopeptide 
compositions and to obtain structural information. The MS/MS data was 
acquired in both negative mode (without ion-pairing reagent) and in positive 
ion mode, after the ion-pairing reagent was added. In both cases, the 
precursor ions were activated for 30 ms with activation Q of 0.25 and an 
isolation width of 3 Da.  Activation amplitudes were in the range of 19-29 % 
as defined by the instrument software.   
       
2.3 Results and Discussion 
2.3.1 Compositional analysis of eTSH glycopeptides  
Edman (N-terminal) chemistry provides reliable sequence information 
for amino acids in an unknown peptide.33 This technique was used to verify 
the actual sequence of the amino acids of the peptide moieties attached to 
the glycan structures generated in this study. Three main peptide sequences 
consisting of LENHTQ, NIT and TINTT were identified, which corresponded 
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to the glycosylation sites at αAsn82 , αAsn56,  and βAsn23, respectively. Based 
on the Edman sequencing data, it was apparent that small quantities of 
several other peptide sequences were also present.  These corresponded to 
shorter variants of these glycopeptides.  
The peptide sequences obtained from Edman sequencing data were 
exported to a visual basic algorithm, which was used in conjunction with the 
high resolution FTICR-MS data (See Figure 2-1) to obtain all the reasonable 
glycan compositions that matched previously characterized glycan structures 
in the bovine and human hormones. The identified glycopeptide structures 
are shown in Table 2-1. The calculated mass error for all the assigned 
compositions was less than 2 ppm.  The data in this table indicates that a 
heterogeneous mixture of the glycopeptides, all of which were either mono- 
or di-sulfated, were identified from this hormone.  
Figure 2-1 shows the mass spectrum acquired in the negative ion 
mode of the identified glycopeptides found in eTSH. Glycans from two 
glycosylation sites were identified corresponding to N56IT and TIN23TT of the 
α and β subunit of this hormone, respectively, and they are uniquely labeled 
on the mass spectrum. The majority of the glycan structures attached to the 
α subunit peptide, N56IT, were hybrid monosulfated glycans, whereas the 
one identified from the β subunit (TIN23TT) was a disulfated, fucosylated, 
complex-type glycan. No glycans were identified corresponding to the 
LEN82HTQ site. 
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The glycans’ structures from the hormone (TSH) used in this study 
have been previously characterized by Green and Baenziger.11 In the 
previous analysis, the metabolically radiolabeled sulfated glycans were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and their structures were elucidated by endo- and exo-
glycosidase digestion in combination with high performance liquid 
chromatography (HPLC).11 The same glycan structures were obtained by 
Harvey et. al using MALDI-MS.23 Because each of the glycan’s structures 
from this hormone have been fully characterized previously, matching the 
masses of the glycan portions to the already identified glycan structures 
allows us to fully know the sequence, branching and the linkage of the 
monosaccharides within each structure. Therefore, the glycopeptides 
generated from this hormone can be considered as an ideal set of 
“standards,” for analyzing the fragmentation trends of these compounds, 
during MS/MS analysis.   
These glycopeptides vary with respect to carbohydrate type, number of 
sulfate groups, and peptide moiety present (see Table 2-1), and the effect of 
each of these features on the MS/MS data, along with the effect of the 
charge state, is compared herein.  This investigation will enable other 
investigators to use (-) ESI-MS/MS and ion-pairing MS/MS to characterize 
the structures of unknown sulfated glycopeptides. 
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2.3.2 Comparison of (-) ESI-MS/MS data based on 
2.3.2.1 Number of SO3 groups present 
Figure 2-2(a) and (b) are (-) ESI-MS/MS data of the doubly charged 
ions containing either one or two SO3 groups. The two glycopeptides at m/z 
942 and 1104 have the same peptide moiety but differ in their glycan 
composition and the number of SO3 groups. Had the composition of the 
singly sulfated glycopeptide been unknown, the MS/MS data would 
potentially be confusing since the loss of SO3 is not observed in Figure 2-
2(a). Instead, only a few cross-ring cleavages were observed, and the base 
peak at m/z 920 is due to loss of CO2. Other product ions in the spectrum at 
m/z 1456, 892, and 428 correspond to 0,2A, 1,3A, and 0,2X cross-ring 
cleavages, respectively. Since 0,2 X and 0,2 A are complementary ions, 
resulting from cleavage of the carbohydrate that is attached to the peptide, 
the presence of either or both ions could be used to identify the peptide 
moiety of the glycopeptide.  The 0,2X ion corresponds to the peptide moiety 
plus 83 Da (a portion of the carbohydrate) whereas the 0,2 A ion is the 
remaining portion of the carbohydrate. In the case of an unknown N-linked 
glycopeptide structure, if the mass difference between the precursor and the 
product ions in (-) MS/MS is greater than 196 (Asn+83), and if this difference 
does not correspond to a glycosidic cleavage, the observed ion can be 
assigned as a cross-ring (0,2 A) cleavage. The peptide moiety identified for 
this particular glycopeptide corresponded to NIT. (While only one example of 
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a singly sulfated, doubly charged glycopeptide is shown, all other similar 
compounds in this study underwent the same dissociation pathways). Based 
on these data, it is evident that (-) MS/MS data for monosulfated 
glycopeptides can only identify the peptide and confirm the presence of a 
glycopeptide, but it cannot verify whether it is sulfated or not.  This is a 
significant limitation:  Detecting the presence of the SO3 group is essential, 
because incorporation of this group on the glycan portion of a glycoprotein 
transforms that glycan into a unique structure that has the potential to be 
recognized by a specific receptor.1
The disulfated ion at m/z 1104 in Figure 2-2(b) indicates a loss of SO3 
group from the base peak.  This information is useful in confirming that this 
species is sulfated. Other prominent peaks at m/z 890 (0,2A) and 1926 (Y5α) 
are due to cross-ring and glycosidic cleavages respectively. The 0,2A ion 
could be used to identify the peptide moiety, which is NIT for this case, and 
the Y5α ion is due to the loss of HexNAc and SO3, indicating that this 
glycopeptide is sulfated on a terminal HexNAc (assuming this loss was due 
to one bond cleavage).   
These results show that the structural information obtained from the 
mono- and di-sulfated glycopeptides is dependent on the number of SO3 
groups present. Regardless of the number of sulfates present, the structural 
information obtained for the glycan portion was minimal, using this method. 
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2.3.2.2 Different glycosylation sites 
 (-)ESI-MS/MS data of two disulfated glycopeptides from different 
glycosylation sites shown in Figure 2-2(b) and (c) indicate that a 0,2A ion is 
observed in both cases. This ion can be used to identify the peptide moieties 
and therefore distinguish between the two glycosylation sites. While the 
presence of Y5α and Y5α,5β,1β ions at m/z 1926 and 1846 (Figure 2-2(b), (c)), 
respectively, are useful in confirming these ions are glycopeptides, they are 
inadequate in providing significant structural information of the glycan 
portions attached to the two identified peptides (NIT and TINTT). Since the 
amount of structural information obtained from the two glycosylation sites 
was similar, it was concluded that the fragmentation patterns observed 
during (-) ESI-MS/MS experiments of these species is independent of the 
peptide moiety.  
 
2.3.2.3 Different charge states 
To maximize the amount of structural information, MS/MS data from 
all observed charge states were compared. As shown in Figure 2-2(a), no 
conclusive structural information was obtained from the doubly charged 
monosulfated ion (m/z 942). However, substantial structural information was 
obtained from the singly charged ion (m/z 1885) as illustrated in Figure 2-
2(d). In addition to the cross-ring cleavages observed from the doubly 
charged ions, several glycosidic cleavages and a neutral loss of SO3 were 
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observed. These ions can be used to verify the composition, identify the 
partial sequence of the monosaccharides present and determine the type of 
N-glycan present. For example, the presence of Y5α (m/z 1602) and Y4β (m/z 
1723), eliminate the possibility that this is a complex-type glycan. Assuming 
that the trimannosyl chitobiose core is intact, these ions indicate that the type 
of N-linked glycan must be a hybrid structure.  Furthermore, 0,2A (m/z 1456) 
and B5 (m/z 1336) ions can collectively give information on the peptide 
moiety present in the glycopeptide (B5 corresponds to loss of the peptide 
moiety attached to a core HexNAc). These results indicate that the amount of 
structural information obtained depends on the charge state of the ion in 
question, and the singly charged glycopeptides provide more structural 
information than the doubly charged species.  (Other singly charged 
glycopeptides in this study also produced MS/MS data that could be used to 
obtain a similar amount of structural information about the glycopeptide). 
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Figure 2-1. FTICR-MS of sulfated glycopeptides from eTSH. The peaks with 
ovals represent glycans from N56IT glycosylation site of the alpha subunit. 
Peaks with squares represent glycans from TIN23TT glycosylation site of the 
beta subunit of eTSH.  
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 Figure 2-2. Comparison of (-)ESI-MS/MS data for sulfated glycopeptides. 
(a) MS/MS of a doubly charged monosulfated glycan from N56IT 
glycosylation site; (b) MS/MS of a doubly charged di-sulfated glycan from 
N56IT glycosylation site; (c) MS/MS of a doubly charged disulfated glycan 
from TIN23TT glycosylation site; (d) MS/MS of singly charged monosulfated 
glycan from N56IT glycosylation site. Description of the symbols used for the 
structural formulae can be found in the foot note to Table 2-1. 
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Table 2-1: Sulfated glycopeptides of eTSH identified using (-)ESI-FTMS 
 
Glycopeptide  
structures 
Charge   
carrier 
Observed
m/z 
Calculated  
m/z 
Mass error  
(ppm) 
(1) 
NIT
SO4  
 
[-2H] 
[-H] 
 
861.3020 
1723.6136
 
861.3012 
1723.6102 
 
0.9288 
1.9726 
(2)
NIT
SO4  
 
[-2H] 
[-H] 
[+Na+ -2H] 
 
942.3280 
1885.6661
1907.6476
 
942.3272 
1885.6630 
1907.6449 
 
0.8490 
1.6440 
1.4154 
(3)            
      
NIT
SO4  
 
[-2H] 
 
1023.3549
 
1023.3540 
 
0.8795 
(4)
NIT
SO4  
 
[-2H] 
 
1064.3819
 
1064.3805 
 
1.3153 
(5)
NIT
SO4
SO4
 
[-2H] 
[+Na+ - 3H] 
 
1104.3597
1115.3510
 
1104.3589 
1115.3499 
 
0.7244 
0.9862 
(6)     
[-2H] 
 
1177.3890
 
1177.3879 
 
0.9343 
(7)  
[-2H] 
[+Na+ -3H] 
 
1278.4363
1289.4272
 
1278.4356 
1289.4266 
 
0.5475 
0.4653 
NIT
SO4
SO4
                             = HexNAc        = Hexose        = Fucose 
 
 
 
 
 
 
TI
NTT
SO4
SO4
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 2.3.3 Useful structural information based on fragmentation 
characteristics observed in  (-)ESI-MS/MS 
As described earlier, the presence of 0,2X and/or 0,2A ions, observed in 
all cases, can be used as diagnostic ion/s for identifying the peptide moiety of 
the glycopeptide. This allows characterization of these glycopeptides in a 
glycosylation site-specific fashion. Based on the observed fragmentation 
patterns, the amount of structural information obtained was dependent on the 
number of SO3 groups present and the charge state of the ion. Specifically, it 
was noted that for all doubly charged ions, when two SO3 groups were 
present, the loss of SO3 was observed as the base peak, and one or two 
glycan related cleavages were also observed, confirming these ions as 
sulfated glycopeptides. However, the abundant loss of SO3 group from the 
precursor ion resulted in the loss of information about the position of sulfation 
on the glycopeptide. On the other hand, when one SO3 group was present, 
no loss of SO3 was observed; instead, a loss of CO2  was observed as the 
base peak. In this case, no conclusive information was obtained to confirm 
these ions as sulfated glycopeptides.  These results imply that more than one 
SO3 group must be present in order to confirm the presence of the SO3 
group for doubly charged sulfated glycopeptides undergoing MS/MS 
fragmentation in the negative ion mode.  While changing the number of 
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sulfates has a significant effect on the fragmentation of the glycopeptides, 
changing the peptide present had no observable effect on the MS/MS data. 
The amount of structural information obtained was also found to be 
dependent on the charge state of the ions. It was observed that when 
monosulfated ions were doubly charged, the loss of SO3 group was not 
observed and no useful structural information was obtained. Moreover, for 
the singly charged state of the same ion, loss of SO3 group was observed 
during MS/MS, and substantial structural information was obtained. Based on 
this comparison, it is evident that the singly charged ions give more structural 
information than their doubly charged counterparts. This implies that the 
presence of the singly charged ions is necessary in order to obtain useful 
structural information for monosulfated glycopeptides. Unfortunately most of 
the ions observed were doubly charged ions, as shown in Figure 2-1. 
Therefore if all the glycopeptide compositions assigned contained only one 
SO3 group, it would be impossible to obtain any useful information on the 
doubly charged form of these species.  (Observation of singly charged 
species is limited by the upper mass limit of the instrument). This limits the 
overall structural information obtained from this approach. 
 
2.3.4 New Approach: The use of ion-pairing with MS/MS  
 The information obtained from (-) ESI-MS/MS for the sulfated 
glycopeptides described above can be enhanced by performing MS/MS on 
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the ion-pair complexes of the glycopeptides.  To obtain ion-pairing MS/MS 
data, in the positive ion mode, the sulfated glycopeptides were combined 
with Lys-Lys-Lys (3K) in solution, forming an ion-pair complex.  This ion-pair 
complex results from the non-covalent interaction of the SO3 group present in 
the glycopeptide with a basic peptide, as shown in Figure 2-3. This 
interaction stabilizes the SO3 group thereby promotes dissociation pathways 
in the positive ion mode that are significantly different than those observed in 
the negative ion mode, during MS/MS experiments. The basic tripeptide, 3K, 
was selected as the ion-pairing reagent, since it has proven to be the most 
effective peptide for binding to sulfated glycans and glycopeptides.25 Table 2-
2 represents all the deprotonated doubly charged ions observed in (-) ESI-
MS along with the expected m/z values of their corresponding ion-pair 
complexes that could be observed, when 3K is combined with the eTSH 
digest. The ions in bold show which ion-complexes were detected after 
incorporating the ion-pairing reagent. 
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Figure 2-3. Formation of ion-pair complexes for MS/MS analysis. 
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 Figure 2-4. Comparison of MS/MS data for ion-pair complexes with Lys-Lys-
Lys (3K). (a) MS/MS of a doubly charged monosulfated glycan from N56IT 
glycosylation site; (b) MS/MS of doubly charged disulfated glycan from N56IT 
glycosylation site; (c)MS/MS of a doubly charged disulfated glycan from 
TIN23TT glycosylation site.  
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 2.3.5 Comparison of MS/MS data of ion-pair complexes based on 
2.3.5.1 Number of SO3 groups present  
As explained earlier, MS/MS data of monosulfated doubly charged ion 
in Figure 2-2(a) (m/z 942) did not provide useful structural information. 
However, after the incorporation of the ion-pairing reagent and performing 
MS/MS in the positive ion mode, more informative product-ions were 
observed.  See Figure 2-4(a). Most of the prominent ions were a result of one 
or more B- or Y-type glycosidic cleavages. These can be used to verify the 
composition as well as to provide information on the sequence and branching 
of the glycan structure. In Figure 2-4(a), B2α (m/z 889) [Y3β]2+,(m/z 983) and 
[Y4β]2+ (m/z 1064) ions not only confirm the presence of the SO3 group but 
also indicate its location on the terminal [HexNAc-HexNAc] portion of the 
glycopeptide. This information was not available before adding an ion-pairing 
reagent (Figure 2-2(a)).   
The pattern of product ions obtained after the addition of the ion-
pairing reagent can also be used to define the class of N-linked glycan 
present. For example, in Figure 2-4(a), the presence of ions, Y3α (m/z 1239) 
and Y4α (m/z 1401) eliminate the possibility of the N-glycan class being a 
complex-type glycan, since these ions must be from a high-mannose branch; 
whereas the [Y3β]2+ (m/z 983) ion identifies the remaining branch of the 
glycopeptide that contains the SO3 group. Therefore, this glycopeptide is 
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definitely a bi-antennary hybrid structure.  This is also supported by the 
sequential order of Y- and B- ions of the other prominent peaks in the 
spectrum. Identifying the type of N-linked glycan present is important 
because different types of these N-linked glycans can have different 
biological functions.  
In addition to obtaining information about the glycan structure, this 
MS/MS data is also useful to confirm the composition of the peptide.  The 
presence of the Y1 ion denotes the glycosylation site, because this ion 
corresponds to [HexNAc+NIT]. This ion, when present in MS/MS spectra of 
ion-pair complexes, can be used to identify the peptide moiety.  While the Y1 
ion’s presence can be used to confirm the composition of the peptide, when 
a likely peptide sequence is hypothesized, it would be difficult to identify 
which ion in the spectrum would correspond to the Y1 ion, had the peptide 
composition been completely unknown.  
 The information obtained from these results collectively allow the full 
characterization of doubly charged monosulfated glycopeptide by providing 
structural information on the glycan portion (sequence, branching, and type 
of N-linked glycan present), confirming the peptide moiety, and confirming 
the presence/location of the SO3 group.  Similar monosulfated ion-pair 
complexes fragmented in a similar manner.  See supplemental Figure 2-2.   
Disulfated glycopeptides were also investigated.  These 
glycopeptides, like their monosulfated counterparts, exclusively form 1:1 
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complexes with the ion-pairing reagents.  The MS/MS data of one of the 
complexes that contains a disulfated glycopeptide is in Figure 2-4(b).  It 
shows a fragmentation pattern that is similar to the complex in Figure 2-4(a). 
The main difference is the loss of the SO3 group, which is the base peak in 
Figure 2-4(b).  This ion is not observed in Figure 2-4(a). This difference is 
due to the fact that the single SO3 group present in the mono-sulfated ion is 
already non-covalently linked to the basic peptide, 3K, which stabilizes it and 
thus minimizes the loss of SO3 in the monosulfated ion-pair complexes. This 
observation is further supported by the appearance of the ions m/z 889, 
1051, and 983 (doubly charged) corresponding to HexNAc2+SO3--3K, Hex-
HexNAc2+SO3--3K, and NIT+HexNAc4Hex2+SO3--3K, respectively (Figure 2-
4(b)). The presence of these ions clearly indicates that covalent bonds were 
broken preferentially, instead of cleaving the non-covalent bond between the 
SO3 group and 3K. 
The results obtained in the spectra in Figure 2-4(a) and (b) show that 
an ion corresponding to loss of SO3 is the only significant difference in the 
fragmentation pattern of the glycopeptides with varying numbers of SO3 
groups present.   However, when the ion-pairing data is compared to the (-) 
MS/MS data, a dramatic increase in structural information was observed.  
The product ions that were observed from ion-pair complexes not only 
identified the peptide moiety but also confirmed the glycan moiety 
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composition, the actual position of the SO3 group, the sequence, branching 
pattern, and the type of N-linked glycan present. 
2.3.5.2 Different glycosylation sites  
  Since it has been demonstrated that under certain conditions, the 
peptide moiety in a glycopeptide drives the fragmentation pathways during 
MS/MS experiments,25,26 it is important to determine the effects of the 
peptide on the fragmentation of these species.   Our results show that there 
is no observable change in fragmentation patterns in (-) ESI-MS/MS data, 
when the peptide was different (Figure 2-2(b) and (c)).  MS/MS data of the 
same ions after the addition of an ion-pairing reagent in Figure 2-4(b) and (c) 
again indicates that changes in the peptide composition (from NIT to TINTT) 
did not affect the mass spectral data.  Both spectra are dominated by Y- and 
B-type ions, providing sequence and branching information of the glycans 
present.  As illustrated before, these ions can also be used to confirm the 
composition and the type (complex) of N-glycans present.  Since the 
glycopeptide ions, shown in Figure 2-4(b) and (c), have similar glycan 
moieties, certain ions, such as the B ions (m/z 889 and 1051) appear in both 
spectra. These ions can be used to infer the location of the SO3 group (on 
HexNAc-HexNAc) within the glycopeptide.  The Y1 ion, corresponding to m/z 
550 in Figure 2-4(a)) and m/z 752 in Figure 2-4(b), identifies the peptide 
moieties found on these glycopeptides as NIT and TINTT, respectively.  
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These results imply that changing the peptide has no significant effect 
on the fragmentation patterns of the attached sulfated glycans observed in 
MS/MS experiments. Thus characterization of these glycans in a 
glycosylation site-specific manner is possible without the peptide moiety 
complicating the mass spectra.  Additional MS/MS data of other ion-pair 
complexes observed in this study can be found in Supplemental Figure.   
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 Supplemental Figure: These spectra support the fact that the fragmentation 
trends for the ion-pair complexes described herein of can be generalized to 
other sulfated glycopeptides. 
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2.3.6 Application to unknown glycopeptides 
In the mass spectral data in Figure 2-1, two prominent ions appear at 
m/z 1186 and m/z 1228.  The compositions of these ions do not appear in 
Table 2-1, because a logical glycopeptide structure could not be assigned, 
using peptide sequences from the Edman data in combination with 
previously-characterized glycans for this hormone.  To demonstrate the utility 
of the method presented herein, and to more fully characterize this 
glycoprotein sample, both these ions were subjected to (-) ESI-MS/MS 
experiments and ion-pairing MS/MS experiments.   
2.3.6.1 Example 1: Use of MS/MS to differentiate two isobaric structures  
In the first example (Figure 2-5), two possible glycan structures are 
presented.  One of the glycans (structure 1) has not been identified 
previously, and one of them (structure 2) has been previously described.  
The measured mass that corresponds to the ion is m/z 1186.8856, while the 
calculated m/z obtained for these species is m/z 1186.8852 for structure 1 
and m/z 1186.8859 for structure 2. Both have a mass difference of less than 
1 ppm from the measured mass.  Since they are isobaric structures, the high-
resolution MS data could not discriminate them.  Both structures are 
biologically relevant, so it is important to conduct further analysis in order to 
confirm the correct structure. The peptide portions (in both examples 1 and 
2) of these glycopeptides, though not identified by Edman data, are possibly 
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present, since both of these peptide sequences represent shorter versions of 
peptides that have been identified by the Edman data.  
MS/MS in negative ion mode 
 MS/MS experiments were performed in the negative ion mode to 
determine which of the two possible structures in Figure 2-5 best 
corresponds to m/z 1186.8856. The product ions are in Table 2-3A; they 
were compared against all the possible fragment ions that would be 
generated by the two structures proposed in Figure 2-5.  The loss of SO3 
from the precursor ion to generate the base peak, corresponding to [M-2H-
SO3]2-, suggests that this is a disulfated glycopeptide.  Since both structure 1 
and structure 2 are disulfated, the presence of this ion could not be used to 
discriminate between the two species. While no logical fragmentation 
assignments matched m/z 593 and 890 for structure 1, these ions could be 
assigned to structure 2, as 0,2X and 0,2A ions, respectively, indicating 
structure 2 as the correct structure. These ions identify the peptide moiety as 
LENH. This data suggests that structure 2 is the correct structure.  
MS/MS of ion-pair complex 
The product ions obtained from MS/MS conducted on the ion-pair 
complex are summarized in Table 2-3B. Several ions observed in the table 
were consistent with only one of the two structures. For example the product 
ion at m/z 715 corresponds to peptide moiety, LENH, attached to GlcNAc 
and is consistent with the peptide identified in the negative ion mode. Product 
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ions at m/z 1608, 1649, 1811, and 1891 explicitly indicate that structure 2 is 
the only possible structure, since these ions exclusively correspond to 
glycopeptide fragments where the glycan portion is attached to LENH. A few 
of the ions could not be used to verify the glycopeptide composition, but they 
provided useful structural information about the location of the SO3 group 
within the glycopeptide. For example, product ions like m/z 889 and 1051 
verify that the SO3 group is attached to a terminal [HexNAc-HexNAc] portion 
of the glycopeptide. These ions could be deduced from either structure 1 or 
2, so they were not used to discriminate between the two structures.   
 
 
NIT
 
Observed m/z: 1186.8856 
Calculated m/z: 1186.8852 
Mass error: 0.3370 ppm. 4
2SO 
 
Structure 1   
 
 
 
 
SO4
NH
SO4
LE
 
Observed m/z: 1186.8856 
Calculated m/z: 1186.8859 
Mass error: 0.2528 ppm.
 
 Structure 2 
 
 
 
Figure 2-5. Two glycopeptide candidates that could correspond to m/z 1186. 
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Figure 2-6. MS/MS of an “unknown” glycopeptide (a) in negative ion mode 
(b) in positive ion mode, after adding an ion-pairing reagent. 
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Table 2-2: Ion-pair complexes of sulfated glycopeptides that 
 were first identified from (-)ESI-MS data 
 
Glycopeptide [M-2H]2- M [3K+M+2H]2+ [3K+M+3H]3+
1 861.3 1724.6 1064.5 710.0 
2 942.3 1886.7 1145.5 764.0 
3 1023.4 2048.7 1226.5 818.0 
4 1064.4 2130.8 1267.5 845.4 
5 1104.4 2210.7 1307.5 872.0 
6 1177.4 2356.8 1380.6 920.7 
Unknown 1 1186.9 2375.8 1390.0 927.0 
Unknown 2 1227.9 2457.8 1431.1 954.4 
7 1278.4 2558.9 1481.6 988.1 
 
[M-2H]2- represents the doubly charged ions’ m/z observed in (-)ESI-MS.   M 
is the molecular mass of the glycopeptide before adding the ion-pairing 
reagent; 3K =  ion-pairing reagent, which has a mass of 402.3 Da.  
[3K+M+2H]2+ and [3K+M+3H]3+ correspond to the m/z for the doubly and 
triply charged ion-pair complexes that could be observed in positive ion 
mode. Peaks in bold correspond to complexes that were detected. 
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Table 2-3: Identification of the correct structure for m/z 1186 by MS/MS  
A) Product ions from (-)MS/MS 
 
Product 
ion 
Observed 
(m/z) 
 
Assignment 
Product ions 
consistent with 
Structure 1 
Product ions 
consistent with 
Structure 2 
1146  [M-2H-SO3]2- Yes Yes 
593 [0,2X]-1 from 
Structure 2 
No Yes 
890  [ 0,2A]2- from 
Structure 2 
No Yes 
 
B) Product ions from MS/MS of the ion-pair complex 
 
Product ion 
Observed 
(m/z) 
 
Assignment 
Product ions 
consistent with
Structure 1 
Product ions 
consistent with 
Structure 2 
889 HexNAc2 + SO3---3K Yes Yes 
1051 HexNAc2 Hex + SO3---3K Yes Yes 
715 LENH+HexNAc No Yes 
1608 LENH+HexNAc3Hex3 No Yes 
1649 LENH+HexNAc4Hex2 No Yes 
1811 LENH+HexNAc3Hex3 No Yes 
1891 LENH+HexNAc3Hex3 No Yes 
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By comparing the data in Tables 2-3A and B, it is clear that both MS/MS 
methods are useful in obtaining the peptide composition for this particular 
glycopeptide.  These data also clearly show that the ion-pairing approach 
can not only be used to verify the glycan composition, but it can also be used 
to infer the location of the sulfate within the glycopeptide. 
 
2.3.6.2 Example 2: Use of MS/MS analysis for structural information 
MS/MS in negative ion mode 
Figure 2-6 (a) represents (-) MS/MS of another unknown glycopeptide, 
m/z 1228. Based on the fragmentation patterns observed in the negative ion 
mode, the presence of 0,2A ion at m/z 963 identifies the peptide moiety as 
INTT, and the apparent loss of SO3 from the precursor ion to generate the 
base peak suggests that this is a disulfated glycopeptide. Using this 
information, a glycopeptide structure can be proposed that is consistent with 
the high-resolution data, the peptide assignment (INTT), and previously 
characterized glycan moieties.  This structure is shown on the spectrum in 
Figure 2-6(a).  The presence of Y5α,1β at m/z 1846 identifies the loss of 
fucose, along with the loss of  SO3 and terminal HexNAc, whereas the 
presence of Y1β /0,2A ion at m/z 1780 further confirms the peptide moiety and 
the likely position of the fucose at the core HexNAc. Unfortunately, this 
information is inadequate to completely verify the structure of the glycan. 
(+)MS/MS of ion pair complex 
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Figure 2-6 (b) represent MS/MS of the ion-pair complex of the same 
glycopeptide shown in Figure 2-6 (a). The presence of Y1 and Y1,1β ions at 
m/z 797 and 651 identify the peptide as INTT. These ions also confirm the 
presence of a fucose, and where it is located (on the core HexNAc). 
Presence of B3α and B2α ions at m/z 1051 and 889 identify the location of 
SO3 on the terminal [HexNAc-HexNAc]. These ions also identify the 
presence of a complex branch (HexNAc-HexNAc-SO3+3K) in this 
glycopeptide. The loss of SO3 from the precursor ion, as the base peak, 
confirms this to be a disulfated glycopeptide. Assuming triamannosyl core is 
intact, the abundant glycosidic cleavage ions can be used to infer the 
structure.  Since fucose is the only monosaccharide that is lost without a 
concerted loss of sulfate, fucose must be the only terminating 
monosaccharide.  This implies that the two sulfate groups are each capping 
a HexNAc-HexNAc disaccharide branch, as depicted in the figure.  All the 
observed glycosidic cleavage ions support this assignment. Assuming this 
glycopeptide was a complete unknown, this information can explicitly identify 
and characterize the unknown sulfated glycopeptide: Not only was the 
sequence, branching pattern, and the type of glycan identified, but also the 
peptide and the number of SO3 groups present were determined.   
From the two MS/MS approaches, it is evident that the use of MS/MS 
in the negative ion mode is the better approach to identify the peptide moiety 
of unknown glycopeptides, when Edman data is unavailable or when sample 
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quantity is limited. This is because, unlike in the positive ion mode, only one 
or two peaks of lower mass are observed. However, MS/MS data of ion-pair 
complexes are very useful in identifying the location of SO3, the composition, 
the sequence, branching and the type of N-linked glycans present. 
 
2.4 Conclusion 
The results from this study clearly demonstrate the efficacy of using 
ion-pairing MS/MS to fully characterize sulfated glycopeptides in a 
glycosylation site-specific fashion, an approach that is complementary and in 
most cases superior to MS/MS analysis in negative ion mode. While the 
negative mode MS/MS data was useful at identifying the peptide moiety, it 
provided minimal glycan structural information.  This information was 
dependent on the number of SO3 groups and the charge state of the ion. In 
contrast, the ion-pairing method provided a wealth of structural information 
about the glycan portion in addition to being useful for identifying the peptide 
moiety.  The information obtained from MS/MS of the ion-pair complexes can 
be used to determine the branching, sequence, and type of N-glycan present 
in a sulfated glycopeptide. This is because MS/MS of the corresponding ion-
pair complexes provided several glycosidic cleavage ions. This information 
was readily available from all ion-pair complexes observed, regardless of the 
number of SO3 groups present or the charge state of the ion.  
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CHAPTER 3 
Simplification of mass spectral analysis of acidic glycopeptides using 
GlycoPep ID. 
 
Reprinted by permission from Anal Chem.  2007, 79, 3065-3074. Copyright 
2007 American Chemical Society 
 
3.1 Introduction 
Glycosylation is a ubiquitous post-translational modification that 
occurs in most secreted and membrane-bound proteins.1-4 This process is 
known to influence various structural and functional properties of the 
glycosylated proteins. For example, glycosylation affects protein folding,1,2 
solubility,3,5 antigenicity,1,6-8 biological activity,2,3 half-life in circulation1,2,9 and 
is also important in protein-carbohydrate interactions.1,5 Changes in 
glycosylation have been implicated in several diseases such ascancers10 and 
congenital disorders.11 Some of these modifications involve sulfation and/or 
sialylation of the attached glycan moiety, and these groups transform the 
modified protein into a unique structure with different biological properties. 
Because these modifications are of eminent biological significance, their 
analysis is the focus of this study.  
 A thorough analysis of glycosylation on proteins involves 
characterizing the composition of the glycans present at each glycosylation 
site.   When only one glycosylation site is present on a protein, the 
carbohydrates can be cleaved from the protein - either chemically or 
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enzymatically - and characterized separately.12 However, this approach has 
limited utility when more than one glycosylation site is present on a protein, 
because information about which carbohydrates originated from which 
glycosylation sites is lost prior to analysis.  To retain this information, a 
different analysis strategy must be employed.  Glycosylated proteins can be 
analyzed by digesting the protein and characterizing glycopeptides by mass 
spectrometry.2-8,13-40  This approach is advantageous because once the 
structure is characterized, the identified peptide portion of the glycopeptide 
can be used to determine where the carbohydrate is attached on the protein.  
As described below, this strategy needs some development before it can be 
implemented in a routine fashion.    
When proteolytic digestion is used for the analysis of glycopeptides, 
most studies usually employ trypsin as the protease, since its cleavage sites 
are at specific amino acid residues, and the sites are well known.  Thus, the 
peptide sequences that are components of the glycopeptides are readily 
predictable, provided a protein sequence is available.  Since all the possible 
peptide sequences are known a priori, assigning peptide compositions to the 
glycopeptides is fairly straightforward, and it can be accomplished using a 
variety of approaches. However, proteolysis of the glycoprotein using trypsin 
has several limitations.  Detecting the glycosylated peptides, which have 
lower ionization efficiency than nonglycosylated peptides, is one major 
obstacle.  Additionally, missed tryptic cleavages, which are known to occur, 
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significantly complicate data analysis.5-8,12  Finally, some glycosylated 
proteins are not highly susceptible to tryptic digest, and others contain 
glycosylation sites that are near each other; thus they yield glycopeptides 
with more than one glycosylation site on the same glycopeptide. 7,8,20,37 For 
example, Cutalo et al. could not characterize five glycosylation sites in 
gp120, an HIV envelope glycoprotein, due to incomplete trypsin digestion 
and the presence of multiple glycosylation sites within one peptide.7 This 
prevented a complete glycosylation site-specific analysis of the attached 
glycans.  
To overcome the limitations described above, several researchers 
have began using digestion enzymes like proteinase K or pronase; which 
proteolyze proteins in a non-specific fashion. 17-20,25 Using these non-specific 
enzymes result in a mixture of glycopeptides that contain significantly shorter 
peptide sequences, and these glycopeptides are less challenging to detect 
by MS analysis for a couple of reasons.  First, sections of the protein that are 
not glycosylated become almost completely digested, so non-glycosylated 
peptides do not appear in the same mass range as the glycopeptides.25 
Therefore, these two species can be readily distinguished from each other. In 
addition, the hydrophobicity of the small nonglycosylated peptides that are 
present after the digest are quite different from that of glycopeptides, so they 
can be rapidly separated from glycopeptides using a variety of fractionation 
strategies.  While digestion with non-specific enzymes provides a clear 
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advantage over trypsin in terms of data acquisition, it can be almost 
impossible to identify the peptide portion of these glycopeptides.  This is 
because the amino acid residues present in the peptide portions of 
glycopeptides generated from a non-specific enzyme like proteinase K can 
vary greatly; they can contain two to five amino acid residues including the N-
glycosylation site.38 As a result, efficient and reliable methods are required to 
explicitly identify the peptide portion for these glycopeptides.  
So far, only a few methods are currently available for helping to 
identify the peptide portion when glycoproteins are proteolized in a non-
specific manner. For example, when pronase or proteinase K is used to 
produce glycopeptides, the peptide portion can be identified by either 
comparing the mass of the glycosylated peptide with the nonglycosylated 
peptide (after being subjected to endoglycosidase digestion)20,25 or by using 
Edman chemistry.17-19,39   The former method is less reliable than Edman 
chemistry, since it identifies the peptide based on the mass difference, and 
hence it is not a feasible solution when analyzing complex mixtures.  Edman 
chemistry’s advantage is that the exact amino-acid sequences can be 
determined, but this approach requires the glycopeptides to be isolated from 
the nonglycosylated components before analysis, and Edman data from 
complex glycopeptide mixtures is also very difficult to interpret.  Finally, this 
technique supplies aggregate data about all the peptide sequences that are 
present, but it does not link the peptide sequence specifically to each of the 
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glycopeptides detected during MS analysis.  Both Edman Chemistry and 
endoglycosidase digestion also suffer the limitation that additional chemical 
reactions need to be performed to obtain the peptide information, which 
means more sample and more experiment time is required.  In positive ion 
mode, ECD is also helpful, but this requires that the glycopeptides are at 
least in the +2 charge state, so these methods are not feasible for acidic 
glycopeptide analysis.41 Consequently, an alternative approach for peptide 
identification during glycopeptide analysis is highly desirable.  
Herein, we propose a novel approach that is facile and highly effective 
in identifying the peptide moiety of glycopeptides generated using a non-
specific enzyme. The approach utilizes our newly developed web-based 
program, GlycoPep ID.  This program determines the peptide portion of 
glycopeptides by calculating the theoretical m/z of 0,2X ion that can be 
generated from a glycoprotein of interest.  GlycoPep ID will generate a table 
of the predicted peptide sequences with their corresponding m/z values, and 
a list of predicted m/z’s of the 0,2X ions that would be generated for each 
peptide.  The 0,2X ion is listed in the table because this ion has been shown 
to be a characteristic for acidic glycopeptides undergoing CID.19 Once the 
predicted 0,2X ions are obtained, product ions present in CID experiments are 
searched against this table to locate a match.  Matched ions identify the 
peptide portion of the glycopeptide.  The versatility of this method is 
demonstrated in the identification of the correct peptide moieties of 
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previously characterized sulfated glycopeptides from a proteinase K digest of 
equine thyroid stimulating hormone (eTSH). This glycoprotein consists of 
three glycosylation sites that are heavily glycosylated with a varying degree 
of sulfation at each site.19 The peptide identification method is also extended 
to identifying the peptide moieties of glycopeptides from a more complicated 
glycoprotein, follicle stimulating hormone (FSH), that consists of four 
glycosylation sites, each containing various degrees of sialylation, sulfation, 
or both sialylation and sulfation. All the peptide moieties identified in this 
study were previously verified with Edman data in conjunction with high-
resolution FTICR-MS analysis. The present strategy has several advantages 
over the previously used approaches for identifying the peptide portions for 
these glycopeptides. It has lower sample consumption and analysis time, but 
more importantly composition information about every glycopeptide present 
in a complex mixture can be obtained in a single series of CID experiments. 
 
 
85
3.2 Experimental/Methods 
3.2.1 Enzymatic digestion of eTSH and eFSH with Proteinase K 
Proteolytic digestion of equine thyroid stimulating hormone (eTSH) 
and follicle stimulating hormone (eFSH) glycoproteins to generate 
glycopeptides was performed by Dr. George Bousfield of Wichita State 
University as described in the protocol by Bousfield et. al.42 Briefly, each 
glycoprotein was reduced, alkylated and desalted before digesting with 
proteinase K.42  The dried digests from eTSH and eFSH were then subjected 
to Superdex peptide gel filtration chromatography.19, 39  The glycopeptide 
fraction was collected, dried, and analyzed as described below. 
 
3.2.2 Glycopeptides preparation for mass spectrometry analysis 
The dried glycopeptide sample was dissolved in water and diluted with 
MeOH:H2O (4:1) containing 0.3% acetic acid, to constitute a final 
concentration of 0.03 μg/μL.  This solution was introduced into the mass 
spectrometer by direct infusion using a syringe pump at a flow rate of 5 
μL/min. 
3.2.3 CID experiments 
CID experiments were performed using electrospray ionization (ESI) 
in the negative ion mode on a linear ion trap-Fourier Transform Ion Cyclotron 
Resonance mass spectrometer, LTQ-FTICR MS, (Thermo Finnigan, San 
Jose, CA) to identify the peptide moiety for each glycopeptide analyzed. All 
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CID data were acquired on LTQ. The precursor ions were selected with an 
isolation width of 3 Da and activated for 30 ms. The activation qz  was 
maintained at 0.25.  Activation amplitudes were in the range of 15-29%, as 
defined by the instrument software.  Data was acquired and processed using 
Xcalibur 1.4 SR1 software (Thermo Finnigan San Jose, CA).  The 
glycopeptide compositions were validated based on previous 
characterizations of these samples.19,39 
3.2.4 Data Analysis 
Data from CID experiments were analyzed using our newly developed 
in-house web-based program, GlycoPep ID.   GlycoPep ID provides a web 
interface (Figure 3-1) that enable the user to specify the experimental 
parameters and the peak list from the CID data.  The input is processed 
using the user specified settings that are described in the next section.  
GlycoPep ID generates a table of the predicted peptide sequences, the 
theoretical peptides’ m/z values, and a list of predicted m/z’s of the 
characteristic signature product ion,  0,2X , resulting from the fragmentation of 
glycopeptides.  Data analysis was performed by comparing the peak lists 
obtained from CID experiments with list of theoretical m/z‘s of the 0,2X ion.  
When a single match is found, the 0,2X ion is used to determine the peptide 
portion of the glycopeptide.  In the case where more than one match is 
found, the existence of the 0,2A ion, the complimentary ion to 0,2X, is 
examined in the CID data.  Both 0,2X and  0,2A  ions are used to determine the 
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peptide portion of the glycopeptide.  GlycoPep ID calculates the m/z value for 
0,2A ions by subtracting the mass of a theoretical “0,2X neutral loss” directly 
from the precursor ion.  As a result, when 0,2A ions are to be calculated, the 
user must input the singly charged form of the precursor ion.   
 
3.3 Results and Discussion 
3.3.1 GlycoPep ID Overview 
GlycoPep ID is a freely accessible web-based program that we 
developed specifically to identify the peptide portion of glycopeptides.  The 
glycopeptides may be generated from proteolytic cleavage with either a 
specific or non-specific enzyme.   This manuscript exclusively describes 
GlycoPep ID’s use in identifying the peptide portion of glycopeptides using 
proteinase K.  To identify the peptide portion, the user inputs the protein 
sequence and the experimental parameters used, which include the enzyme 
(proteinase K or trypsin), cysteine modification, charge state, and mass 
tolerance in ppm or Da into the program (Figure 3-1).  The user also inputs 
the extracted peak list from the CID data.  An abundance threshold of 10% is 
set for all ions in the selected mass range to be included in the peak list. The 
user has the option to calculate the 0,2A ion, which is complementary to the 
0,2X ion.   
Once all the necessary parameters are input and submitted, GlycoPep 
ID first determines how many N-linked glycosylation sites are present in the 
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protein of interest.  Once the glycosylation sites are determined, it generates 
a table consisting of all possible peptide sequences from these glycosylation 
sites that range between two to six amino acids in length that includes the 
glycosylation site. In addition to the peptides that could be present, GlycoPep 
ID lists theoretical m/z’s for each of the peptides, the corresponding m/z’s of 
0,2X ion, and plausible matches from CID data input by the user.   When a 
single match is obtained, the peptide portion is identified.  When more than 
one match is obtained, the CID data is searched for the 0,2A ion. In this case, 
the correct match from the output is one that has both 0,2X and 0,2A ion in the 
mass spectrum.  It should be noted that all masses reported by the program 
are monoisotopic.   
GlycoPep ID was implemented using an open source server side 
scripting language PHP running under an Apache web server on a Linux 
system.  The program can be accessed from the website, 
http://hexose.chem.ku.edu/sugar.php, under Tools.   Future updates of 
GlycoPep ID will include variable peptide modifications, charge carriers other 
than H+, and the ability to choose other proteases for theoretical digestion. 
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 Figure 3-1: A screenshot of GlycoPep ID. 
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AMINO ACID SEQUENCE OF EQUINE THYROID STIMULATING HORMONE 
(eTSH) 
 
Alpha Subunit 
  
FPDGEF TTQDCPECKL RENKYFFKLG VPIYQCKGCC FSRAYPTPAR SRKT  
       
MLVPKN56ITSESTCCVA KAFIRVTVMG NIKLEN82HTQC YCSTCYHHKI  
  
 
 
Beta Subunit  
 
FCIPTEYMMH VERKECAYCL TIN23TTICAGY CMTRDINGKL FLPKYALSQD 
 
VCTYRDFMYK TVEIPGCPDH VTPYFSYPVA VSCKCGKCNT DYSDCIHEAI  
 
KANYCTKPQK SYVVEFSI  
 
 
 
AMINO ACID SEQUENCE OF EQUINE FOLLICLE STIMULATING HORMONE 
(eFSH)  
Alpha subunit 
FPDGEFTTQDCPECKLRENKYFFKLGVPIYQCKGCCFSRAYPTPARSRKTMLVPK 
 
N 56ITSESTCCVAKAFIRVTVMGNIKLEN82HTQC YCSTCYHHKI  
 
 Beta subunit 
NSCELTN7ITIAVEKEECGFCISIN24TTWCAGYCYTRDLVYKDPARPNIQKTCTFKEL
VY 
 
ETVK VPGCAHHADS LYTYPVATAC HCGKCNSDST DCTVRGLGPS 
YCSFGDMKE  
 
 
Figure 3-2(a): Amino acid sequence of eTSH obtained from Swiss-Prot. Its 
three glycosylation sites, αAsn56, αAsn82, and βAsn23 are highlighted.(b) : 
Amino acid sequence of eFSH obtained from Swiss-Prot. Its four 
glycosylation sites, αAsn56, αAsn82, βAsn7, and βAsn23 are highlighted. 
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3.3.2 Method validation 
The glycoproteins used in this analysis are heterodimeric pituitary 
hormones, thyroid stimulating hormone (TSH) and follicle stimulating 
hormone (FSH) containing three and four glycosylation sites, respectively.   
Each of the glycosylation sites is known to have a wide diversity of N-linked 
glycans. These glycoproteins have been extensively studied and therefore 
they are ideal model systems for developing a method for glycopeptide 
analysis.  The protein sequences are shown in Figure 3-2.  
   In the first set of experiments, the glycoprotein, eTSH, was 
employed to demonstrate the viability of using GlycoPep ID in identifying the 
peptide portion of sulfated glycopeptides. Preliminary data from eTSH 
indicated that (-) ESI-MS/MS of sulfated glycopeptides always produced both 
0,2X and 0,2A ions, which are complementary ions resulting from a cross-ring 
cleavage of the carbohydrate attached to the peptide as shown in Figure 3-
3.19 The goal of the work presented herein is to use the information that this 
cleavage occurs readily as the basis of our approach for identifying the 
peptide portion of any negatively charged glycopeptide, using GlycoPep ID.   
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Figure 3-3: The 0,2X and 0,2A cross-ring cleavage, which occurs during CID 
experiments of negatively charged glycopeptides. The ions produced by this 
cleavage are used for identifying the peptide portion of glycopeptides. 
 
 (-)ESI-MS/MS data obtained from all the previously identified sulfated 
glycopeptides of eTSH was analyzed by comparing the product ion masses 
to the list of predicted masses of the 0,2X ion from GlycoPep ID.   Figure 3-4a 
and b shows (-) ESI-MS/MS data of two glycopeptides that originate from two 
different glycosylation sites in eTSH.  In this data, several product ions are 
present that could potentially correspond to the expected 0,2X ion that would 
identify the peptide moiety.  In order to identify the 0,2X ion, the data was 
analyzed using GlycoPep ID.   The following parameters were used for 
GlycoPep ID: the peak list from the (-) ESI-MS/MS data in Figure 3-4a , the 
eTSH protein sequence, proteinase K for enzyme, charge state of -1, mass 
tolerance of ±0.1 Da, carbamidomethyl for cysteine modification.  GlycoPep 
ID outputs the prediction table for eTSH and a plausible 0,2X candidate from 
the peak list (Figure 3-5A).   In this analysis, only m/z 630 is identified as a 
matching ion, as shown in Figure 3-5A. This implies that TIN23TT is the 
correct peptide present in this glycopeptide.  
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A similar interpretation can be made for the mass spectral data in 
Figure 3-4b. When the peak list of the product ions in Figure 3-4b is input 
with the following parameters: eTSH protein sequence, proteinase K for 
enzyme, charge state of -1, mass tolerance of ±0.1 Da, carbaimidomethyl for 
cysteine modification, GlycoPep ID outputs more than one plausible 0,2X 
candidate. The matches corresponded to the peptides NIT/TIN/INT (m/z 
428.2), LENHT(m/z 694.3), and NITSES (m/z 731.3)  respectively within a 
mass error of ±0.1 Da.   Because more than one match was generated, the 
data was re-analyzed to calculate the 0,2A ion.  In this analysis, the singly 
charged precursor ion at m/z 2355.8 was input, per the requirements of the 
algorithm.   The corresponding prediction table and the list of plausible 0,2X 
and 0,2A candidates are shown in Figure 3-5B.  Using the masses of the 
singly charged 0,2A ions output from GlycoPep ID, the mass spectrum was 
inspected to identify either singly charged or doubly charged forms of these 
ions.   Of the three potential peptide sequence ions identified by GlycoPep 
ID, only m/z 428 has its complementary ion (m/z 963) present in the 
spectrum.  Therefore, the correct peptide match corresponds to either N56IT 
or IN23T. While the MS data cannot discriminate among sequences of 
isomeric peptides, previous analysis on this sample indicated that all the 
glycopeptides containing only N, I, and T amino acid residues originated from 
the alpha subunit (α-Asn56).  As a result, the correct peptide moiety for this 
disulfated glycopeptide is identified as N56IT.    
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The peptide moieties for all the other sulfated glycopeptides in eTSH 
are identifiable in a similar manner.  MS/MS data was acquired on each 
previously characterized eTSH glycopeptide,19 and a list of all the observed 
product ions for each glycopeptide was generated. Analysis of this data using 
GlycoPep ID identified one unique peptide moiety for each glycopeptide 
analyzed. The results of this analysis for all glycopeptides in eTSH are 
summarized in Table 3-1.  This table contains a total of nine sulfated 
glycopeptides that are either mono- or di-sulfated. From these sulfated 
glycopeptides, four different peptide moieties (N56IT, TIN23TT, IN23TT, 
LEN82H) were identified; these peptides corresponded to all the three 
glycosylation sites in eTSH. Although in some cases the peptide sequence 
could not be identified exclusively, for example, m/z 529 in Table 3-1 
matches three peptide masses in the prediction table that GlycoPep ID 
generates, TIN23T, IN23TT, and N23TTI. All these possible peptides map to 
the same glycosylation site. Since the goal is to determine which 
carbohydrates are attached to which glycosylation site, this small ambiguity 
in the peptide sequence is irrelevant in this case. In every case, the peptide 
identified using this strategy matched the validation data, where a 
combination of Edman sequencing and FTICR-MS was required to obtain the 
same information.19 
Based on these results, it is quite evident that (-)ESI-MS/MS data can 
be used in conjunction with GlycoPep ID to identify the peptide moiety 
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present in sulfated glycopeptides that are generated by proteinase K 
digestion, and this approach has significant advantages over the current 
methods of obtaining this information.   This method is more sensitive than 
Edman sequencing, and it is a more selective technique, since it provides 
information on each glycopeptide specifically, instead of simply supplying 
aggregate information on the entire glycopeptide mixture.  
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 Figure 3-4: MS/MS data for doubly charged ions of sulfated glycopeptides from 
different glycosylation sites of eTSH. The peptide and glycan portions of these 
glycopeptides have been previously characterized using a combination of Edman 
chemistry and FTICR-MS.19  (a) MS/MS data for disulfated glycopeptide from Asn82 
of the β-subunit. (b) MS/MS data for disulfated glycopeptide from Asn56 
glycosylation site of the α-subunit 
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 Figure 3-5: Peptide prediction table from GlycoPep ID containing the predicted and 
matched m/z’s for 0,2X and/or 0,2A ions from sulfated glycopeptides of eTSH. 
.   
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Figure 3-6: CID spectra representing doubly charged ions of glycopeptides from 
eFSH. The glycopeptide compositions were previously characterized using Edman 
chemistry and FTICR-MS.39 (a) and (b) represent MS2 and MS3 data respectively of 
an example of glycopeptides that are exclusively sialylated; (c) and (d) represent an 
example of MS2 and MS3 data respectively, obtained from glycopeptides that are 
both sialylated and sulfated.
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Table 3-1: Peptide identification for sulfated glycopeptides from eTSH 
 
Parent 
ion 
m/z 
Observed 0,2X 
ion 
Observed 0,2A 
ion 
Peptide 
identified 
Peptide from 
validation 
dataa
b[861.3]2- [428.1]- [1294.1]- NIT NIT 
b[942.3]2- [428.1]- [1456.1]- NIT NIT 
b[1023.4]2- [428.1]- [1618.1]- NIT NIT 
b[1064.4]2- [428.1]- [1700.1]- NIT NIT 
c[1104.4]2- [428.1]- [889.6]2- NIT NIT 
c[1177.4]2- [428.1]- [962.6]2- NIT NIT 
c[1186.9]2- [593.2]- [889.7]2- LENH LENH 
c[1227.9]2- [529.2]- [962.6]2- NTTI/TINT/INTT INTT 
c[1278.4]2- [630.2]- [962.6]2- TINTT TINTT 
 
a Data from reference 19. 
b Previously characterized mono-sulfated, glycopeptides.  
c Previously characterized di-sulfated, glycopeptides. 
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3.3.3 Application to complex negatively charged glycopeptides from 
eFSH  
Having demonstrated the efficacy of using GlycoPep ID in identifying 
the peptide portion of sulfated glycopeptides from (-) ESI-MS/MS data, this 
method is extended to identify the peptide moieties from more complex 
glycopeptides, such as those from follicle stimulating hormone (FSH).  FSH 
belongs to the same pituitary glycoprotein hormone family as TSH. One main 
difference between FSH and TSH is the fact that unlike TSH, FSH contains 
four glycosylation sites, and glycopeptides released from this hormone 
contain glycans that are exclusively sialylated and those that are sulfated and 
sialylated.   The FSH sample was prepared in the same manner as the TSH 
sample, and the data was analyzed using the same approach as well.  The 
amino acid sequence for FSH is readily available from Swiss-Prot, and is 
shown in Figure 3-2.   Two example analyses of this hormone using 
GlycoPep ID are described below.  These examples are for a glycopeptide 
that is exclusively sialylated and one that is both sialylated and sulfated.  
 
3.3.4 CID experiment data for glycopeptides containing sialic acid only 
MS/MS experiments on sialylated glycopeptides indicated that loss of 
sialic acid is very favorable, and when this occurs, virtually no other product 
ions are present in the spectrum.  This is consistent with previous 
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researchers’ findings who have documented the extreme lability of sialic 
acid.13, 40 Despite the lability of sialic acid, it does not represent a significant 
obstacle for our analysis, since MS3 experiments can be performed on the 
product ion that corresponds to the loss of sialic acid, and the product ions 
from that experiment can be used to identify the peptide. 
Figure 3-6a and b represent an example of MS2 and MS3 data 
obtained from activation of a doubly charged glycopeptide containing two 
sialic acids. As shown in Figure 3-6a, MS/MS data of this glycopeptide at m/z 
1442 provides no informative product ions. The base peak, m/z 1296, results 
from loss of sialic acid.  An MS3 experiment performed on this ion is shown in 
Figure 3-6b and the peak list from MS3 data was input in GlycoPep ID.  The 
following input parameters were used: the eFSH protein sequence, 
proteinase K for enzyme, charge state of -1, mass tolerance of ±0.1 Da, 
carbaimidomethyl for cysteine modification, and calculation for 0,2A ion was 
not selected.  GlycoPep ID generated only one product ion, m/z 616, from 
the potential 0,2X ions in the prediction table within a mass error of 0.1 Da 
(Figure 3-7A).  This product ion corresponds to the peptide sequence, SINTT 
from the prediction table.  For the glycopeptide depicted in Figures 3-6a and 
b, the complementary 0,2A ion is observed in the mass spectrum at m/z 1975 
in Figure 3-6b; therefore SIN24TT is definitively identified as the peptide 
moiety in this glycopeptide. This peptide sequence is consistent with that 
identified from the high-resolution FTICR-MS data and Edman data.39 The 
 
 
102
final results for this glycopeptide, along with others from FSH, are 
summarized in Table 3-2.  Again, in each case the identified peptide matched 
the validation data. For glycopeptides at m/z 1376, 1449, 1500, 1543, and 
m/z 1573, the 0,2A ions are not observed, because they are outside the upper 
mass limit of the instrument used in this analysis.  This does not affect the 
overall results for this study, since each of these disialylated glycopeptides 
only had one product ion that matched the predicted masses of 0,2X ions in 
prediction table in Figure 3-7A. Thus, the presence of their complementary 
0,2A ions is not necessary for the correct peptide to be identified. However, 
had there been more than one product ion that matched the predicted 
masses of 0,2X ions in the prediction table, the presence of the 
complementary 0,2A ion would be necessary to verify the correct peptide 
moiety.  
 
3.3.5 CID experiments for glycopeptides containing both sulfate and 
sialic acid   
Figure 3-6c and d represent CID data obtained from a doubly charged 
ion of a glycopeptide from eFSH that contains both sialic acid and sulfate. As 
in the case of glycopeptides containing sialic acid only, the MS/MS data of 
glycopeptides containing both sialic acid and sulfate provide no useful 
information for identifying the peptide present. Since sialic acid is the most 
labile group in the molecule, loss of sialic acid is the only product ion 
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observed during MS/MS experiments, at m/z 1314 (Figure 3-6c).  When MS3 
experiments are performed on this ion, several product ions are observed 
that could correspond to the peptide moiety for this glycopeptide; see Figure 
3-6d.  Analysis of this data using GlycoPep ID generated three plausible 
matches: LENHTQ, KLENHT, and SCELTN.  Specifically, m/z 822 could 
correspond to the peptides LEN82HTQ or KLEN82HT and m/z 804 correspond 
to the peptide SCELTN. The abundance of m/z 804 is ~28% while that of m/z 
822, which is the most abundant product ion in the mass range of interest, is 
100%.   Using the same approach as described above, a search for each 
complementary 0,2A ion was performed on the CID data so as to identify the 
correct peptide moiety. A close inspection of the mass spectrum in Fig. 6-3d 
reveals that only m/z 822 has its singly charged complementary ion present 
at m/z 1805. This information indicates that either LEN82HTQ or KLEN82HT is 
the peptide present in this glycopeptide. Since LEN82HTQ and KLEN82HT are 
isobaric compounds, they can be discriminated by the high-resolution data 
from FTICR-MS, which confirms LEN82HTQ is the correct peptide39 as 
indicated by Table 3-2. Even though the low-resolution method could not 
distinguish between LENHTQ and KLENHT, both these glycopeptides map 
to the same glycosylation site, so distinguishing between the two sequences 
is not necessary.   
CID data from all the other glycopeptides that are both sialylated and 
sulfated produce similar information.  A summary of all the glycopeptides 
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from FSH investigated in this study is shown in Table 3-2.  All the identified 
peptide moieties from GlycoPep ID match the assignments made when these 
samples were previously analyzed, using a combination of Edman 
sequencing and FTICR-MS analysis.39  
 
3.4 Conclusion  
The results from this study clearly demonstrate that the peptide 
moieties of negatively charged glycopeptides can be identified by matching 
product ions in CID data to a prediction table generated in an automated 
fashion, from the web-based program , GlycoPep ID.   The versatility of the 
method using a non-specific protease, proteinase K and the automated data 
analysis of glycosylation in a site specific manner was demonstrated by 
identifying the peptide moieties of glycopeptides from two different 
glycoprotein hormones that were exclusively sialylated or sulfated, or were 
both sialylated and sulfated. All 27 peptide moieties in this study were 
correctly identified by GlycoPep ID and validated using data from a 
combination of Edman chemistry and high resolution FTICR-MS analysis.  
This technique represents an important advance in glycosylation profiling 
because it solves one of the most difficult problems of using proteinase K in 
glycopeptide analysis: Determining where the enzyme cleaved the protein.     
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 Figure 3-7: Peptide prediction table from GlycoPep ID containing the predicted and 
matched m/z’s for 0,2X and/or 0,2A ions from sulfated glycopeptides of eFSH. 
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Table 3-2: Summary of all analyzed glycopeptides from eFSH using 
GlycoPep ID. 
 
m/z for 
parent ion 
 (2H+) 
 
Type of 
modication 
 
m/z for 
0,2X 
observed 
 
m/z for 0,2A  
observed 
 
Peptide 
identified 
Peptide 
from 
validation 
data#
 
1043* 
 
Sulfation 
428 1659 N7/56IT/LTN7 N7/56IT 
 
1104* 
 
Sulfation 
428 1700 N7/56IT/LTN7 N7/56IT 
 
1189 
Sialylation 
and sulfation 
428 1659 N7/56IT/LTN7 N7/56IT 
 
1227* 
 
Sulfation 
529 [962.82]2- IN24TT IN24TT 
 
1262 
Sialylation 
and sulfation 
428 1805 N7/56IT/LTN7 N7/56IT 
 
1301* 
 
Sulfation 
822 1700 LEN82HTQ/
KLEN82HT 
LEN82HTQ 
 
1313 
Sialylation 
and sulfation 
529 1805 IN24TT IN24TT 
 
1347 
 
Sialylation 
428 1975 N7/56IT/LTN7 N7/56IT 
 
1356 
Sialylation 
and sulfation 
616 1805 SIN24TT SIN24TT 
 
1376 
 
Sialylation 
428 Out of range N7/56IT/LTN7 N7/56IT 
 
1386 
Sialylation 
and sulfation 
822 1659 LEN82HTQ/
KLEN82HT 
LEN82HTQ 
 
1398 
 
Sialylation 
529 1975 IN24TT IN24TT 
 
1442 
 
Sialylation 
616 1976 SIN24TT SIN24TT 
 
1449 
 
Sialylation 
428 Out of range N7/56IT/LTN7 N7/56IT 
 
1460 
Sialyaltion 
and sulfation 
822 1805 LEN82HTQ/
KLEN82HT 
LEN82HTQ 
 
1500 
 
Sialylation 
529 Out of range IN24TT IN24TT 
 
1543 
 
Sialylation 
616 Out of range SIN24TT SIN24TT 
 
1573 
 
Sialylation 
822 Out of range LEN82HTQ/
KLEN82HT 
LEN82HTQ 
 
*Ions that provided peptide information in MS/MS. Peptide information for 
the rest of the ions was obtained during MS3 experiments. 
# Data from reference 39 
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CHAPTER 4 
 
Comparison of LC/ESI-FTICR MS vs MALDI-TOF/TOF MS for 
glycopeptide analysis of a highly glycosylated protein: HIV Envelope 
glycoprotein 
 
4.1 Introduction 
Glycoproteomics is a newly emerging field that involves the 
characterization of protein glycosylation. It is widely accepted that 
glycosylation is by far the most common post translational modification 
present in both eukaryotic and prokaryotic proteins.1, 2 This modification plays 
a major role in proteins’ biological and cellular processes, and it influences 
their physiochemical properties.3-5  Glycans have also been shown to play a 
vital role in various parasitic, bacterial and viral disease infections.6 For 
instance, interactions and fusion of the human immunodeficiency virus (HIV) 
with its target host cells is mediated by its envelope protein, gp160, which is 
extensively glycosylated protein with over 50% of its mass comprising of 
glycans.7-10 The high population and diverse range of glycan structures on 
this protein act as a shield for the virus against the immune system by 
masking epitopes that could be targeted for immune attack.8, 11-17 
Consequently, defining the structures and locations of glycans in the HIV 
envelope protein is important in understanding how variation in glycosylation 
affects the protein’s function,  and in this particular example, glycosylation 
information may also provide valuable structural insight into current HIV 
vaccine candidates,  which is  useful in vaccine development.  (Ref eden’s 
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paper) . To acquire this information, sensitive, rapid, and reliable methods for 
mapping and profiling glycosylation in proteins are required. 
Unlike in the proteomics and glycomics fields where methods of 
analysis are well established, analytical methods of analysis in the 
glycoproteomics field are still underway. Mass spectrometry (MS) has gained 
a widespread use in protein glycosylation analysis and has become an 
indispensable, powerful analytical technique in the field of glycoproteomics, 
due to its high sensitivity and selectivity.  Analysis of protein glycosylation by 
mass spectrometry is typically achieved by two main approaches: Either 
glycans can be released from the peptide backbone enzymatically or 
chemically, or the glycoprotein can be subjected to a protease digestion, 
producing a mixture of peptides and glycopeptides. The latter approach is 
advantageous to releasing glycans from the protein, since it does not require 
extra sample manipulation. and it allows for site-specific glycosylation 
profiling.18 However, there are several obstacles encountered when using a 
glycopeptide-based MS analysis. For example, glycopeptides exhibit poor 
ionization efficiency and their signal is usually suppressed by non-
glycosylated peptides. In addition, most glycosylation sites contain various 
glycoforms, and each glycoform may exist at low concentration in the total 
glycopeptide mixture.19, 20 To obviate these obstacles, it is often necessary to 
perform an enrichment or chromatographic separation prior to MS analysis. 
Several studies have addressed this issue and proposed effective 
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enrichment or/and chromatographic methods that can be utilized prior to MS 
analysis of glycopeptides.3, 20  
Although glycopeptide-based MS approaches are typically used for 
glycoprotein analysis, so far there is no consensus as to which MS approach 
would provide the most glycosylation information, especially for a complex 
glycoprotein. Recent advances in glycopeptide-based MS analysis have 
been achieved by two emerging platforms, online LC/ESI-FTICR-MS and 
offline HPLC/ MALDI-TOF/TOF MS. These methods are known for their 
unique high resolution and high mass accuracy capabilities, along with their 
ability to accommodate MS/MS experiments. MALDI-TOF/TOF is widely 
used partly because it has a higher dynamic range and has a high tolerance 
to salts and other contaminants.  Besides, the complexity of data obtained in 
ESI-FTICR-MS due to the presence of multiply charged ions and formation of 
salt adducts greatly complicates data interpretation of heterogeneous 
glycopeptide mixtures.21 However, unlike offline HPLC/MALDI-MS, online 
LC-ESI-FTICR-MS efficiently provides great deal of information in a single 
experiment.22  Furthermore, glycan-specific ions can be selectively identified 
from full MS1 scan and used to trigger subsequent MSn scans during 
chromatographic separation of complex digest mixture, thereby providing a 
plethora of information about the glycopeptides in question.23 On the 
contrary, MSn experiments cannot be performed by MALDI-TOF/TOF MS, 
which limits the amount of information that can be acquired using this 
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platform. In addition, MALDI analyses suffer from matrix-dependent 
ionization and fragmentation processes.24-27 The type of matrix used for 
glycopeptide analysis largely influences the extent and type of fragmentation 
ions produced during MALDI-MS/MS experiments.26  Since neither the 
MALDI nor ESI platforms stand out as a clearly superior approach, we 
performed a head-to-head comparison on both platforms, using a highly 
complex glycoprotein sample, in order to investigate the merits and 
limitations of each method.  
Herein, we present a detailed study to investigate the merits of offline 
HPLC/MALDI-TOF/TOF and online LC-ESI-FTICR when used to provide 
glycosylation information of a recently characterized glycoprotein containing 
31 potential glycosylation sites.28 Specifically, we employed the two platforms 
to analyze the number of glycopeptides and quality of MS data obtained 
during the analysis of the glycoprotein, CON-S gp140∆CFI, a synthetic form 
of the envelope protein found on the HIV virus (gp160).29 To ensure that the 
intrinsic worth of each platform was fully exploited, we determined how well 
each platform could answer several specific research questions that will 
eventually contribute in understanding how glycosylation affects the function 
and immunogenicity of the env protein. These questions included: how many 
of the 31 potential glycosylation sites, if glycosylated, could be detected by 
each technique; what is the extent of glycosylation coverage provided by 
each platform, for each glycosylation site; what type of confirmatory 
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information can be obtained on both the peptide and glycan portions of the 
glycopeptides identified using collision induced dissociation (CID) 
experiments.  Our results revealed significant differences in the glycosylation 
sites detected by using each method, the population of glycoforms identified 
and the type of structural information obtained on either the peptide or glycan 
portion of the identified glycopeptides. These results suggest that the two 
techniques are highly complementary, and when possible, the glycosylation 
information is maximized by combining the two platforms. 
 
4.2 EXPERIMENTAL SECTION 
4.2.1 Materials and Reagents 
Purified CON-S gp140ΔCFI protein was produced as recombinant 
vaccinia virus expressed protein from Duke Human Vaccine Research 
Institute in Durham, as described previously.29 Urea, 
ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT), iodoacetamide 
(IAA), HPLC grade acetonitrile (ACN), ammonium bicarbonate, trizma 
hydrochloride and base, formic acid, 2,5-dihydroxybenzoic acid (DHB), and  
α-cyano-4-hydroxycinnamic acid (CHCA), were all purchased from Sigma-
Aldrich. Proteomics grade trypsin was obtained from Promega (Madison, 
WI). N-Glycosidase F (PNGase F) from Elizabethkingia meningosepticum 
was obtained from CalBioChem (San Diego, CA). Water used for these 
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studies was purified using a Millipore Direct-Q3 Water Purification System 
(Billerica, MA).  
4.2.2 Trypsin digestion of CON-S gp140ΔCFI protein  
Approximately 300 μg of protein was prepared in 100 mM Tris-HCl 
buffer, containing 6M urea and 3mM EDTA, pH 7.5. The protein was reduced 
for 1 hour with 15 mM DTT and alkylated for another hour at room 
temperature with 50 mM IAA.  The excess IAA was neutralized by adding 
DTT, to a final concentration of 40 mM. Extra buffer solution was added to 
reduce the concentration of Urea to about 2M Trypsin was added at a 
protein:enzyme ratio of 30:1 (w/w) to generate glycopeptides. The protein 
solution was incubated overnight at 37 °C. The reaction was quenched the 
following day by adding 1 μL of concentrated acetic acid. Two aliquots were 
removed from the total digest, and each aliquot was subjected to either 
online LC/ESI-FTICR or offline HPLC fractionation, prior to MALDI-TOF/TOF.  
4.2.3 Reverse phase HPLC fractionation 
The tryptic glycopeptides/peptides mixture was purified and separated 
on a Shimadzu model HPLC system. For each run, 20 μL of the tryptic digest 
was injected onto a C18 column (150×4.6mm, 5 μM, Alltech, Deerfield, IL) at 
a flow rate of 1mL/min. Purified water and HPLC grade ACN each containing 
0.1% formic acid were used as mobile phase A and B respectively, with a 
linear gradient from 5% to 40% B over 50 min, followed by a ramp to 95% B 
in 10 min.30 Fractions were manually collected every 1 min for 60 min.  Each 
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fraction was evaporated to dryness on a CentriVap (Labconco Corporation, 
KC, MO) before reconstituting with 10 μL of water.  The reconstituted 
fractions were first screened and analyzed by MALDI-TOF/TOF and all 
fractions containing glycopeptides were then deglycosylated and reanalyzed 
by MALDI-TOF/TOF.  
4.2.4 Deglycosylation 
Reconstituted glycopeptide fractions were enzymatically 
deglycosylated using PNGase F (CalBioChem) by applying the protocol 
recommended by the manufacturer. Briefly, each enriched glycopeptide 
fraction was deglycosylated by adding 4 μL of PNGase F and 25 μL of 20 
mM NH4HCO3 (pH = 8), and then incubated overnight at 37 oC. The reaction 
was stopped by boiling and analyzed by MALDI-MS. 
4.2.5 MALDI-TOF/TOF MS analysis 
A combination of DHB and CHCA (1:1 V/V) matrixes was used and 
mixed with each sample (1:1 by volume).  Approximately 0.75 µL of the 
mixture was spotted on a stainless steel MALDI target plate (Applied 
Biosystems, Foster City, CA) and air-dried. All MALDI MS and MS/MS data 
was acquired in the reflectron mode on an Applied Biosystems 4700 
proteomics analyzer mass spectrometer. The samples were irradiated by a 
355 nm Nd-YAG laser (355 nm) at 200 Hz. The acceleration voltage was 25 
kV. Each mass spectrum was generated by averaging 3200 laser shots. The 
laser intensity was optimized to give the best signal-to-noise ratio and 
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resolution for each sample. All the data were processed in Data Explorer 
version 4.5 (Applied Biosystems). Glycopeptide analysis was performed by 
using the high-resolution MALDI-TOF/TOF MS data in conjunction with our 
previously described web-based tool, (GlycoPep DB),31 to assign 
glycopeptide compositions. The assigned compositions were then confirmed 
by MALDI-MS/MS experiments. 
4.2.6 Capillary LC/ESI- FTICR MS analysis 
Analysis of the tryptic glycopeptides on LC/ESI-FTICR-MS was 
performed by using a Dionex Ultimate capillary LC system (Sunnyvale, CA) 
equipped with a FAMOUS well plate autosampler coupled to a high-
resolution Thermo Finnigan linear ion trap-Fourier Transform Ion Cyclotron 
Resonance mass spectrometer, LTQ-FTICR-MS, (San Jose, CA) equipped 
with a 7 Telsa actively shielded magnet. Samples were loaded onto a 
Famous well plate autosampler and 5 μL of the tryptic digest was injected 
onto an LC Packings C18 PeMapTM 300 column (300 μm i.d ×15cm, 5 μm, 
300 Å). Water and HPLC grade ACN, each containing 0.06% formic acid, 
were used as mobile phase A and B respectively, with a linear gradient 
starting from 5% to 40% B over 50 min, followed by a ramp to 95% B in 10 
min. The eluting solution was directly infused into the mass spectrometer at a 
flow rate of 5μL/min.   
 High resolution data was acquired on the FTICR MS by maintaining 
resolution at 50,000, for m/z 400. The instrument was externally calibrated 
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prior to the analysis, over the entire mass range of interest. The data was 
acquired in the mass range of m/z 800-2000 using a spray voltage of 
approximately 4.0 kV. N2 was used as a nebulizing gas at 20 psi, and the 
capillary temperature was maintained between 200-230 oC. Data was 
acquired and processed using Xcalibur 1.4 SR1 software (Thermo Finnigan 
San Jose, CA).  The glycopeptide compositions were assigned using the 
high resolution data together with GlycoPep DB as described previously.31 
4.2.7 CID Experiments in LC/ESI-FTICR MS 
All MS/MS data was acquired in the linear ion trap of the hybrid LTQ-
FTICR in a data-dependent scanning fashion. Data dependent MS/MS data 
was acquired for the three most intense ions observed in full MS1 scan, using 
a dynamic exclusion window. To maximize the number of data dependent 
MS/MS data collected for the glycopeptides ions observed in full MS1 scan 
data, three more scan events were set with each subsequent scan event 
selecting the 2nd, 3rd and 4th three most intense ions from MS1 data. If a 
neutral loss of a hexose or a HexNAc was detected in these scans, an MS3 
scan event was triggered. Each selected precursor ion was activated for 30 
ms with qz value of 0.25 and an isolation width of 3 Da.  Activation 
amplitudes were in the range of 22-25% as defined by the instrument 
software.   
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4.2.8 Data analysis  
To interpret the high-resolution data acquired from LC/ESI-FTICR MS, 
several steps were undertaken. The first step was to determine if the peaks 
observed in MS1 were glycopeptides or not. In order to verify this, the lower 
mass range region of MS/MS spectra of those peaks were examined for the 
presence of glycan characteristic product ions like m/z 528 
[HexNAc+2Hex+H]+, m/z 690 [HexNAc+3Hex+H]+, m/z 893 (triamannosyl 
chitibose core), or m/z 657 [HexNAc+Hex+Sialic Acid+H]+. If any of these 
ions was observed, the next step was to input the MS/MS peaklist of the 
glycopeptides in question into our newly developed web-based tool, 
GlycoPep ID. A complete description of how this tool operates was provided 
previously.32 Briefly, GlycoPep ID uses characteristic fragment ions, such as 
0,2X ion [Peptide+83-H]- or Y1 ion [Peptide+203+H]+, observed in MS/MS to 
predict the potential peptide portion of the glycopeptides in question. From 
LC/ESI-MS/MS data in the positive ion mode, each of the scan events 
provided a specific characteristic fragmentation ion, Y1 , a glycosidic bond 
cleavage that occurs at the inner core of N-acetyl glucosamine (HexNAc) 
attached to the peptide, and this ion was automatically predicted by 
GlycoPep ID, thus identifying the peptide portion of the glycopeptides in 
question. The identified peptide portion was then inputted into GlycoPep DB, 
described previously31, which utilizes the high resolution MS1 peaklist to 
generate all the plausible glycan compositions attached to that specific 
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peptide. All the glycopeptide compositions outputted were then inspected 
manually and verified by using MS1 and MS/MS data. MS/MS data was also 
used to confirm the assigned glycopeptide compositions and to obtain 
composition information about the glycan portions.  
For MALDI-TOF/TOF data analysis, MALDI-MS/MS data obtained 
from each glycopeptide fraction was first analyzed to identify the 0,2X ion 
[Peptide+83+H]+, a characteristic product ion that is typically observed in 
MALDI-MS/MS data of glycopeptides.  This ion corresponds to the peptide 
portion attached to a portion of the glycan, which remains attached to the 
peptide after the cross ring cleavage.33 The identified peptide portion for 
each fraction was then input into GlycoPep DB; and, using the high-
resolution MS1 peaklist of that fraction, all the plausible glycopeptide 
compositions could be identified. These glycopeptide compositions were then 
verified manually using MS1 and MS/MS data.  
 
4.3 RESULTS AND DISCUSSION 
CON-S gp140∆CFI is a potential candidate for HIV/AIDS vaccine, and 
it is a very heavily N-glycosylated protein with 31 potential glycosylation 
sites.29 Figure 4-1 shows the CON-S gp140∆CFI protein sequence with all 
the potential glycosylation sites highlighted in red.  The peptides boxed in 
green represent all the possible tryptic peptides containing one or more 
potential glycosylation site(s) produced from this protein, with no missed 
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cleavages. The glycosylation on this protein has recently been described,28 
and in that work, glycosylation analysis was demonstrated to be an effective 
technique in correlating glycosylation profiles with vaccine efficacy. The work 
presented here uses this same protein in a case-study detailing the relative 
merits of offline HPLC, followed by MALDI TOF/TOF MS and online LC-ESI-
LTQ-FTICR-MS for glycopeptde analysis.  The protein was subjected to 
typical sample preparation conditions (reduction/alkylation and tryptic digest) 
and analyzed using two of the most powerful MS techniques; LC/ESI-FTICR-
MS and MALDI-TOF/TOF. Figure 4-2 illustrates the analytical protocol 
employed in this study.  After the glycoprotein was digested with trypsin, the 
total digest was divided into two portions. Each portion was subjected to 
either capillary LC/ESI-FTICR MS or HPLC fractionation followed by MALDI-
TOF/TOF MS analysis.  In addition, the reconstituted HPLC fractions 
collected for MALDI-TOF/TOF analysis were also deglycosylated and 
reanalyzed by MALDI-TOF/TOF MS. The glycosylation information content 
(sequence coverage, number and type of glycans) obtained from each MS 
approach was compared to determine the strengths and weaknesses of the 
two methods.   
4.3.1 Assigning glycopeptide compositions 
One of the key challenges in glycopeptide-based MS analysis is 
assigning compositions to the masses observed in MS1 data with a high 
confidence level. This is because it is very possible to assign different 
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glycopeptide compositions to the same mass, even when mass accuracy is 
less than 5 ppm.34 Thus, a comparison was undertaken to determine whether 
LC/ESI-FTICR or MALDI-TOF/TOF MS had advantages in terms of providing 
the most confirmatory information about the glycopeptide compositions 
assigned. To perform this comparison, glycopeptide peaks observed from the 
high-resolution MS1 data of each instrument were subjected to MS/MS 
experiments, and the resulting product ions from each technique were used 
to confirm the glycopeptide compositions assigned based on the high-
resolution MS1 data. Figure 4-3a and b represent MS/MS data from LC/ESI-
FTICR and MALDI-TOF/TOF MS respectively of the same glycopeptide 
observed in both methods. This glycopeptide is used as an example to 
demonstrate the relative merits of MS/MS analysis from each technique in 
providing high confidence assignments for the peptide and glycan 
compositions. 
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Figure 4-1: The protein sequence for CON-S gp140∆CFI with all the 31 
potential glycosylation sites highlighted in red. The peptides boxed in green 
represent all the potentially glycosylated tryptic peptides present in this 
protein with no missed cleavages. 
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Figure 4-2: Work flow to illustrate the protocol used to analyze CON-S 
gp140∆CFI glycopeptides. 
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4.3.1.1 MS/MS data from LC/ESI-FTICR MS 
Figure 4-3a illustrates an MS/MS spectrum, acquired in the linear ion 
trap of the LTQ-FTICR mass spectrometer. This spectrum is populated with 
product ions resulting from glycosidic bond cleavages, which provide 
information about the glycan moiety attached to the peptide. For instance, 
the sequential losses of hexose (162 Da), HexNAc (203 Da), and fucose 
(146 Da) can be identified and used to verify the glycan composition attached 
to the peptide. In Figure 4-3a, the glycan composition for the glycopeptide at 
m/z 1477.15 is confirmed by product ions resulting from glycosidic bond 
cleavage of this glycopeptide. The glycosidic cleavages include sequential 
losses of nine hexoses (mannose residues), confirming the presence of 
Man9, a high mannose type of N-linked glycan.   The glycosidic cleavage 
resulting from a loss of a HexNAc is represented by a square in Figure 4-3a. 
As indicated in this spectrum, the cleavage of all the glycosidic bonds 
present in this glycopeptide are observed up to the innermost N-acetyl-
glucosamine residue (HexNAc), which is attached to the peptide moiety of 
the glycopeptide. This cleavage product corresponds to the Y1 ion or 
[Peptide+203+H]+.  When core fucosylation is present, both 
[Peptide+203+H]+ and [Peptide+349+H]+ are observed. The Y1 ion is a useful 
characteristic product ion and was observed in all MS/MS data for the 
 
 
126
glycopeptides subjected to ESI MS/MS experiments; it provides information 
about the glycan attachment site.  The product ion corresponding to the Y1 
ion can be identified either manually or by simply inputting the MS/MS 
peaklist for this glycopeptide (m/z 1477.15) into GlycoPep ID, 
http://hexose.chem.ku.edu/predictiontable2.php, which automatically outputs 
the potential peptide and its corresponding Y1 ion. (See experimental 
section)  In this case, GlycoPep ID was used to identify the Y1 ion, which was 
identified as m/z 1290.74 (singly charged) and m/z 646.08 (doubly charged) 
and its corresponding peptide moiety, SN453ITGLLLTR. Taken together, the 
glycosidic cleavage product ions explicitly confirm the glycan portion of this 
glycopeptide, and the Y1 ion verifies the peptide composition. However, there 
were no other product ions resulting from cleavage along the peptide 
backbone; thus further confirmation of the peptide sequence was not 
feasible.   
4.3.1.2 MS/MS data from MALDI-TOF/TOF MS 
Figure 4-3b represents MS/MS data obtained from MALDI-TOF/TOF 
of the same glycopeptide shown in Figure 4-3a. As indicated in Figure 4-3b, 
fewer fragmentation ions are observed compared to the ones observed in 
Figure 4-3a. These ions include two sets of cleavage ions at or near the 
innermost HexNAc residue. The two sets of cleavage ions represent the Y1 
ion ([Peptide+203+H]+) and the 0,2X ion ([Peptide+83+H]+). This pair of ions 
was always observed in all glycopeptides subjected to MALDI-MS/MS 
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experiments, regardless of the type of N-linked glycans (high-mannose, 
complex or hybrid) present. Like in MS/MS on the linear ion trap, when core 
fucosylation is present, the Y1 ion, corresponding to [Peptide+349+H]+, is 
observed, along with the 0,2X ion. In Figure 4-3b, Y1 and 0,2X ions are 
observed at m/z 1290.9 and m/z 1170.8 respectively. Besides the set of 
cleavage ions, there were no other glycan related cleavage ions observed in 
the MALDI MS/MS experiments.33 This is because unlike the low energy CID 
in the linear ion trap, MALDI-MS/MS is a high energy process that yields 
predominantly fragmentation ions from peptide bond cleavage.27 As a result, 
MS/MS of the glycopeptide at m/z 2952.55 yields several y and b ions 
resulting from peptide bond cleavage. Thus, this technique provides detailed 
sequence and site-attachment data for the glycosylated peptide but provides 
minimal information about the glycan moiety. 
Overall, MS/MS data acquired from the two high resolution MS 
techniques, LC/ESI-LTQ-FTICR and MALDI-TOF/TOF provided confirmatory 
information in that in both methods, the Y1 ion was always observed. This ion 
was used as a characteristic ion to identify the peptide moiety of the 
glycopeptide in question. The remaining mass of the glycopeptide after 
subtracting the mass of the Y1 ion can be used indirectly to determine the 
glycan moiety for that glycopeptide. In MS/MS in the linear ion trap, the 
characteristic Y1 ion was always observed as the base peak for 
glycopeptides containing high-mannose glycan compositions, but was not the 
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base peak for glycopeptides containing complex or hybrid glycans. In MALDI-
MS/MS, in addition to the Y1 ion, the 0,2X ion was also always observed, and 
either of these two ions formed the base peak. It is worth noting that although 
these ions identify the peptide moiety of the glycopeptide in question by 
providing the mass of the peptide, deglycosylation experiments, which 
identify the peptide with a high degree of confidence since they provide the 
peptide sequence of the deglycosylated peptide, generally identified the 
same peptides as identified by the Y1 ion and the 0,2X ions. This increased 
the confidence level of the identified peptides from both ESI- and MALDI-
MS/MS data.  Furthermore, for smaller mass ions (< m/z 5000) and strongly 
ionizing peptides, like arginine-containing tryptic peptides, the peptide 
sequence could easily be obtained from MALDI MS/MS data without 
deglycosylation. Therefore, MALDI-TOF/TOF provided a higher confidence 
level for identifying the peptide moiety than the LC/ESI-FTICR-MS data.  
However, in terms of the glycan moiety identified by both MS/MS techniques, 
LC/ESI-FTICR provided a higher confidence level than MALDI-TOF/TOF. 
When the two MS techniques are used together, extensive information can 
be obtained both about the peptide sequence and the monosaccharide units 
contained in the glycan.   
4.3.2 Number of glycoforms identified 
Table 4-1 shows the number of glycoforms identified at each 
glycosylation site, detected from both LC/ESI-FTICR and MALDI-TOF/TOF 
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MS. A complete list of all the assigned glycan compositions can be found in 
Supplemental Table 4-1, attached. From Table 4-1, it is quite evident that the 
number of glycans obtained from each glycosylation site differed greatly 
between the two instruments. For instance, from LC/ESI-FTICR MS data in 
Table 4-1, we identified 27 different glycan compositions attached to 
EANTTLFCASDAK peptide whereas, from the same glycosylation site, only 
four glycan compositions were identified using MALDI-TOF/TOF MS. 
However, when another glycosylation site is examined, for example, from the 
peptide LREHFNN361K/EHFNN361K, 35 different glycan compositions 
attached to this site were identified using MALDI-TOF/TOF (Table 4-1) 
whereas from LC/ESI-FTICR MS, only eight different glycan compositions 
were identified from the same site (Table 4-1).  As a result, since the number 
of glycan compositions identified varied from one glycosylation site to the 
other between the two instruments, the best glycan population coverage was 
achieved when the two instruments were used to complement each other.   
Figure 4-4 shows a Venn diagram that demonstrates the glycan 
population coverage for MALDI-TOF/TOF and LC/ESI-FTICR MS.  As 
indicated in this figure, about 130 unique glycan compositions were identified 
using each of the two MS techniques alone. About 90 identical glycan 
compositions were identified by both methods.  Overall, approximately 350 
different glycan compositions were identified from all detected glycosylation 
sites in CON-S gp140∆CFI, using the two high-resolution methods, LC/ESI-
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FTICR and MALDI-TOF/TOF MS.  These results further support the fact that 
the best profile for the glycan population present in a complex glycoprotein is 
best achieved by a combination of both methods.   
 
4.3.3 Identification of the most abundant type of N-linked glycan 
present 
Table 4-1 also shows the most abundant type of N-linked glycans 
identified from each glycosylation site using both LC/ESI-FTICR MS and 
MALDI-TOF/TOF MS.  (Isomeric structures of the ones shown in Table 4-1 
are also possible). All the three types of N-linked glycans, high mannose, 
hybrid and complex type, were detected from all the identified glycosylation 
sites; see Supplemental Table 4-1 attached.  Although the number of glycans 
detected at each site using the two methods differed, in most cases, they 
both provided similar results about the most abundant glycan species 
present at each site. For example, the total number of glycans found 
attached to EHFNN361K/LREHFNN361K using MALDI-TOF/TOF was 35 while 
from LC/ESI-FTICR MS, only eight were detected. However, regardless of 
the significant difference in number of glycans detected, the same glycan 
structure ([Hex9HexNAc2]) was identified as the most abundant species in 
both cases. Additionally, seven of the nine glycosylatd tryptic peptides 
identified by both MS methods produced the exact same glycan composition 
for the most abundant species. The remaining two glycosylated tryptic 
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peptides both contained high-mannose glycans, although the exact 
composition varied slightly between the two instruments. See Table 4-1. This 
shows that the two instruments provided highly consistent information 
regarding the most abundant N-linked glycans present at each glycosylation 
site.  From this table, it can also be seen that out of all the glycosylation sites 
detected by both methods, about 80% of them contained high-mannose N-
linked glycans as the most abundant species. As a result, it can be inferred 
that CON-S gp140∆CFI has a high degree of high-mannose N-linked glycan 
structures.   
In summary, the two MS methods used to analyze this sample 
provided complementary information, both in terms of the number and type of 
glycosylated peptides detected, and in terms of the glycoforms detected at 
each site.  While the number of glycoforms detected varied, in most cases, 
each method identified the same type of glycoform as the most abundant 
species, when the glycopeptide was detectable using both methods.   
 
 
132
 
 
Figure 4-3: A representative example of MS/MS data used to confirm the 
assigned glycopeptides compositions. (a) Illustrates ESI-MS/MS data for a 
doubly charged glycopeptide ion at m/z 1477.15. (b) Indicates MALDI-
MS/MS data of the singly charged form of the same glycopeptides (m/z 
2952.55) as in (a). 
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Figure 4-4: Venn diagram indicating the number of glycan population 
detected by either high resolution LC/ESI-FTICR or MALDI-TOF/TOF or 
both. 
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Table 4-1: A summary of type and number of glycoforms identified from 
CON-S gp140∆CFI 
 
N/A – Not Applicable, glycopeptide peaks were very low in abundance making 
it impossible to identify the most abundant type of glycoform present 
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Figure 4-5: Representative examples of MS1 of high-resolution data 
containing the same glycopeptide peaks for CON-S gp140∆CFI acquired on 
ESI-FTICR and MALDI-TOF/TOF. (a) MS1 spectrum from ESI (b) MALDI 
MS1 spectrum for the similar glycopeptide peaks as ESI MS.
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Table 4-2: Glycosylation sites coverage from high-resolution MS 
 
A)  Tryptic peptides identified by LC/ESI-FTICR MS  
and MALDI-TOF/TOF MS  
No. of 
Potential 
Sites 
FN237GTGPCK/CNDKKFN237GTGPCK 1 
EHFNN361K/ LREHFNN361K 1 
QAHCN337ISGTK 1 
SEN280ITNNAK 1 
NNN413NTN416DTITLPCR 2 
DGGNN466NTN469ETEIFRPGGGDMR 2 
LDVVPIDDNNN190N191SSNYR 2 
N155CSFN159ITTEIR 2 
SN453ITGLLLTR 1 
EAN48TTLFCASDAK* 1 
LINCN201TSAITQACPK* 1 
 
B)  Unique tryptic peptides detected only in LC/ESI-FTICR MS 
 
WN344KTLQQVAKK/ WN344K 1 
AYDTEVHNVWATHACVPTDPNPQEIVLEN87VTENFNMWK 1 
EINN643YTDIIYSLIEESQNQQEK 1 
 
Unique peptides detected only in MALDI-TOF/TOF MS 
TIIVQLN293ESVEIN299CTRPNN305NTR 3 
N245VSTVQCTHGIKPVVSTQLLLN266GSLAEEEIIIR 2 
DQQLEIWDN631MTWMEWER 1 
  
 
C)  Undetected tryptic peptides by both LC/ESI-FTICR  
and MALDI-TOF/TOF MS 
 
LTPLCVTLN129CTNVN135VTN138TTN141NTEEK 4 
GEFFYCN391TSGLFN397STWIGN403GTK 3 
 
* Peptide sequences detected in low abundance in MALDI-TOF/TOF; verified by 
deglycosylation with PNGase F and MS/MS on resulting peptides.
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4.3.4 Glycosylation sites coverage 
 
Theoretically, digestion of CON-S gp140∆CFI with trypsin would 
produce a total of 19 unique tryptic peptides containing one or more potential 
glycosylation site(s), (assuming no missed cleavages), which would account 
for the 31 potential glycosylation sites present in this protein. To determine if 
any of the two MS techniques could identify all the 31 potential glycosylation 
sites, (19 tryptic peptides), we examined the number of tryptic peptides and 
their corresponding number of glycosylation sites detected by each MS 
technique and then compared the results.  
Table 4-2 shows the tryptic peptides (bearing potential glycosylation 
site(s)) and their corresponding number of glycosylation sites detected from 
both MS techniques. As shown in this table, from LC/ESI-FTICR MS, a total 
of 14/19 tryptic peptides each containing one or more potential glycosylation 
sites were detected, which accounted for 18/31 potential glycosylation sites 
present in this protein.  Figure 4-5a is a representative example of MS1 data 
containing glycoforms from two co-eluting tryptic peptides obtained from 
LC/ESI-FTICR MS. As can be seen from this figure, each tryptic peptide 
contained various glycoforms. A complete list of glycoforms from each of 
these tryptic peptides can be found in the Supplemental Table.   
In MALDI-TOF/TOF, two analyses were performed in parallel. The first 
analysis was performed by subjecting each of the reconstituted HPLC 
fractions to MALDI-TOF/TOF analysis. Figure 4-5b illustrates an example of 
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MS1 data from MALDI-TOF/TOF; it contains the same tryptic peptide as that 
shown in Figure 4-5a, from the LC/ESI-FTICR MS data. The compositions of 
the glycoforms shown in this figure can be found in Supplemental Table.  
In the second MALDI analysis, PNGase F was used to deglycosylate 
each of the reconstituted HPLC fractions analyzed in the first experiment. 
This enzyme releases N-linked glycans from the protein, converting the 
asparagine residues (N) from which the glycans are removed into aspartic 
acid (D). As a result, a mass shift of 1 Da is expected to occur for every 
utilized glycosylation site on the peptide, when it is deglycosylated.35 This 
experiment was used to confirm glycopeptides whose abundance was low in 
the high-resolution MALDI-TOF/TOF data. For instance, glycosylated tryptic 
peptides, LINCN201TSAITQACPK and EAN48TTLFCASDAK, were detected 
in low abundance in MALDI-TOF/TOF in the first analysis, making it difficult 
to verify them using MALDI-MS/MS before deglycosylation. However, after 
deglycosylation (second analysis) these tryptic peptides could be confirmed. 
More importantly new tryptic peptides were also detected. For example, two 
tryptic peptides shown in Table 4-2C, LTPLCVTLN129CTNVN135VTN138TT 
N141NTEEK and GEFFYCN391TSGLN397STWIGN403GTK, which contain four 
and three potential glycosylation sites respectively. These tryptic peptides 
were also not detected in LC/ESI-FTICR MS, probably because of their high 
masses, when glycosylated. Another issue with these two peptides that 
hinders their ionization by MALDI-TOF/TOF is the fact that they are 
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terminated in lysine. The lysine containing tryptic peptides are known to 
ionize less efficiently during MALDI analysis than tryptic peptides containing 
arginine residues36, and their ionization efficiency was even more 
compromised since they are multiply glycosylated (and thus large and 
heterogenous). Furthermore, with the high resolution of MALDI-TOF/TOF in 
the reflectron mode, sensitivity especially for higher masses is lower than for 
smaller masses, making it more difficult to detect these glycopeptides in the 
first MALDI-TOF/TOF MS analysis. As a result, it is possible to observe these 
multiply glycosylated peptides after deglycosylation (second analysis) but not 
when glycosylated (first analysis). Overall, from high resolution MALDI-
TOF/TOF analyses, a total of 14/19 potentially glycosylated tryptic peptides, 
corresponding to 21/31 potential glycosylation sites, were identified. 
In cases where full coverage of all the glycosylation sites is desired, 
lower resolution MS techniques like MALDI MS analysis in the linear mode 
can employed to identify the glycan compositions of the glycosylated 
peptides uniquely detected in PNGase F experiments; however, this results 
in glycopeptides mass assignments of lower confidence levels, since the 
assignments are based on average masses rather than monoisotopic 
masses and no MS/MS experiments can be performed to confirm the 
assigned masses.  
Based on these results, it is quite evident that using either one of the 
two high-resolution MS techniques may be inadequate in detecting all the 
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potential glycosylation sites present in a heavily glycosylated protein like 
CON-S gp140∆CFI. As a result, a comparison was performed to determine 
what overlap in sequence coverage the two instruments had, and if there 
was any benefit derived from combining the two MS techniques in terms of 
the number of glycosylation sites detected. A closer look at these results 
obtained from both techniques revealed that only 11/19 potentially 
glycosylated tryptic peptides, accounting for 15/31 potential glycosylation 
sites, were identified from both methods. (See Table 4-2A)  For example, the 
tryptic glycopeptides shown in Figure 4-3a and b were identified from both 
MS techniques. The remaining three and six glycosylation sites were 
uniquely identified from either high resolution LC/ESI-FTICR or MALDI-
TOF/TOF MS, respectively and are listed in Table 4-2B. When the numbers 
of glycosylation sites identified from the two MS techniques are combined, 
17/19 tryptic peptides bearing one or more glycosylation sites are identified 
resulting to a total of 24 of the 31 potential glycosylation sites. This coverage 
is higher than the 18 or 21 glycosylation sites obtained from either LC/ESI-
FTICR or MALDI-TOF/TOF MS, respectively. Approximately 80% 
glycosylation coverage was obtained when the two high-resolution MS 
techniques are used together. This implies that it is important to use both 
techniques in order to increase the probability of detecting as many potential 
glycosylation sites as possible.  Additionally, deglycosylation experiments 
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followed by low-resolution MALDI-MS methods were necessary to afford 
100% coverage in this case.   
4.4 Conclusion   
This study demonstrates the use of two high-resolution MS 
techniques; MALDI-TOF/TOF and LC/ESI-FTICR MS, to provide 
glycosylation information of a potential HIV vaccine candidate, CON-S 
gp140∆CFI, with a high degree of confidence. CID experiments acquired in 
both instruments indicated that ESI-MS/MS in a linear ion trap provided the 
most information about the glycan moiety while MS/MS on a MALDI-
TOF/TOF provided a higher confidence level for confirming the peptide 
portion of the same glycopeptide. When used together, the two instruments 
provided complementary information about the glycopeptide compositions. 
From the high-resolution data of the two instruments, 14/19 tryptic peptides 
were obtained from each MS technique accounting for 18/31 and 21/31 
potential glycosylation sites in this protein from LC/ESI-FTICR and MALDI-
TOF/TOF respectively. When the two instruments were used to complement 
each other, 24/31 tryptic peptides, accounting for about 80% glycosylation 
sites coverage, was obtained, indicating that the best glycosylation site 
coverage is achieved when the two methods are used together.  
In terms of glycosylation data, different populations of N-linked 
glycans comprising of a wide-range of high-mannose, hybrid, and complex 
types N-linked glycans, were identified and characterized in a glycosylation 
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site-specific manner.  Overall, high-mannose glycans were identified as the 
most abundant from both MS techniques. Approximately 350 glycopeptide 
compositions were identified, when data from the two techniques were 
combined. The information presented in this study provides other 
researchers with useful insight about what MS methods are most appropriate 
for glycopeptide analysis, and how those methods can be used 
synergistically to provide optimal glycosylation coverage and high confidence 
assignments.   
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Supplemental Table: Glycopeptide Composition for CON-S gp140 ∆CFI 
from High-Resolution MS 
Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI 
TOF-TOF 
C1 EANTTLFCASDAK [Hex]3[HexNAc]2 √  
 ″ [Hex]3[HexNAc]3 √  
 ″ [Hex]3[HexNAc]3[Fuc]1 √  
 ″ [Hex]3[HexNAc]4 √  
 ″ [Hex]3[HexNAc]4[Fuc]1 √  
 ″ [Hex]3[HexNAc]5 √ √ 
 ″ [Hex]3[HexNAc]5[Fuc]1 √  
 ″ [Hex]3[HexNAc]6[Fuc]1 √  
 ″ [Hex]4[HexNAc]2 √  
 ″ [Hex]4[HexNAc]3 √  
 ″ [Hex]4[HexNAc]3[Fuc]1 √  
 ″ [Hex]4[HexNAc]4  √ 
 ″ [Hex]5 [HexNAc]3 √  
 ″ [Hex]5[HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]3[SO3]1 √  
 ″ [Hex]5[HexNAc]4 √  
 ″ [Hex]6 [HexNAc]2 √  
 ″ [Hex]6[HexNAc]3 √  
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]6[HexNAc]4 √  
 ″ [Hex]7[HexNAc]2 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
 ″ [Hex]4[HexNAc]5 √  
 ″ [Hex]5[HexNAc]3[NeuNAc]2 √  
 ″ [Hex]6[HexNAc]3[Fuc]1[NeuGc]2 √  
 ″ [Hex]7[HexNAc]4 √  
     
 AYDTEVHNVWATHACVPTDP
NPQEVVLENVTEHFNMWK 
[Hex]3[HexNAc]4 √  
 ″ [Hex]3[HexNAc]5 √  
 ″ [Hex]3[HexNAc]6 √  
 ″ [Hex]4 [HexNAc]4 √  
 ″ [Hex]4[HexNAc]5[Fuc]1 √  
 ″ [Hex]4[HexNAc]5[NeuNAc]1 √  
 ″ [Hex]5 [HexNAc]3 [Fuc]1 √  
 ″ [Hex]5[HexNAc]2 √  
 ″ [Hex]5[HexNAc]5 √  
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
C1 AYDTEVHNVWATHACVPTDP
NPQEVVLENVTEHFNMWK 
[Hex]5[HexNAc]5[NeuNAc]1 √  
     
V1-V2 NCSFNITTEIR [Hex]6 [HexNAc]2 √  
 ″ [Hex]7[HexNAc]2 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
 ″ [Hex]3[HexNAc]2 √ √ 
     
V1-V2 NCSFNITTEIR [Hex]3[HexNAc]2[Fuc]1  √ 
 ″ [Hex]3[HexNAc]3  √ 
 ″ [Hex]3[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]4 √ √ 
 ″ [Hex]3[HexNAc]4[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]5  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]6  √ 
 ″ [Hex]3[HexNAc]6[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]3 √ √ 
 ″ [Hex]4[HexNAc]3 [Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]4 √ √ 
 ″ [Hex]4[HexNAc]4 [Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]5[Fuc]1[NeuNAc]1 √  
 ″ [Hex]5[HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3 √ √ 
 ″ [Hex]5[HexNAc]3 [NeuNAc]1 √  
 ″ [Hex]5[HexNAc]4 
[Fuc]1[NeuNAc]1 
√  
 ″ [Hex]5[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]4 √  
 ″ [Hex]5[HexNAc]4[Fuc]1  √ 
 ″ [Hex]5[HexNAc]4[Fuc]1[NeuNAc]1 √  
 ″ [Hex]5[HexNAc]5[Fuc]1  √ 
 ″ [Hex]6[HexNAc]2 √ √ 
 ″ [Hex]6[HexNAc]3 √ √ 
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]6[HexNAc]4 √  
 ″ [Hex]6[HexNAc]5 √  
 ″ [Hex]6[HexNAc]6[Fuc]1 √ √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
V1-V2 NCSFNITTEIR [Hex]7[HexNAc]2 √ √ 
 ″ [Hex]7[HexNAc]3 √  
 ″ [Hex]7[HexNAc]3Fuc1 √  
 ″ [Hex]7[HexNAc]4 √  
 ″ [Hex]8 [HexNAc]2 √ √ 
 ″ [Hex]9 [HexNAc]2 √ √ 
     
V2 LDVVPIDDNNNNSSNYR [Hex]3[HexNAc]2  √ 
 ″ [Hex]3[HexNAc]3 √ √ 
 ″ [Hex]3[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]4  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1 √  
 ″ [Hex]3[HexNAc]5  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]6[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]7[Fuc]1  √ 
 ″ [Hex]4[HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]3 √ √ 
 ″ [Hex]4[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]4[Fuc]1  √ 
 ″ [Hex]4[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]7[Fuc]1  √ 
 ″ [Hex]5 [HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3 √ √ 
 ″ [Hex]5[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]4[Fuc]1  √ 
 ″ [Hex]5[HexNAc]5  √ 
 ″ [Hex]5[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]6[Fuc]1  √ 
 ″ [Hex]5[HexNAc]7[Fuc]1  √ 
 ″ [Hex]6 [HexNAc]2 √ √ 
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]6[HexNAc]3[NeuNAc]1 √  
 ″ [Hex]6[HexNAc]5[Fuc]1  √ 
 ″ [Hex]6[HexNAc]6[Fuc]1  √ 
 ″ [Hex]6[HexNAc]7[Fuc]1  √ 
 ″ [Hex]7[HexNAc]2 √ √ 
 ″ [Hex]7[HexNAc]3  √ 
 ″ [Hex]7[HexNAc]6[Fuc]1  √ 
 ″ [Hex]7[HexNAc]7[Fuc]1  √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
V2 LDVVPIDDNNNNSSNYR [Hex]8[HexNAc]2 √ √ 
 ″ [Hex]8[HexNAc]4 √  
 ″ [Hex]9[HexNAc]2 √ √ 
     
V2-C2 LINCNTSAITQACPK [Hex]3[HexNAc]2 √ √ 
 ″ [Hex]3[HexNAc]3 √  
 ″ [Hex]3[HexNAc]3[Fuc]1 √  
 ″ [Hex]3[HexNAc]4 √  
 ″ [Hex]3[HexNAc]4[Fuc]1 √  
 ″ [Hex]3[HexNAc]5[Fuc]1 √  
 ″ [Hex]3[HexNAc]6[Fuc]1 √  
 ″ [Hex]4[HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]3 √  
 ″ [Hex]4[HexNAc]3[Fuc]1 √  
 ″ [Hex]4[HexNAc]5[Fuc]1 √  
 ″ [Hex]4[HexNAc]5[Fuc]1[NeuNAc]2 √  
 ″ [Hex]5 [HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3 √  
 ″ [Hex]5[HexNAc]3[Fuc]1 √  
 ″ [Hex]5[HexNAc]4[Fuc]1 √  
 ″ [Hex]5[HexNAc]4[Fuc]1[NeuNAc]2 √  
 ″ [Hex]5[HexNAc]5[Fuc]1 √  
 ″ [Hex]6 [HexNAc]2 √  
 ″ [Hex]6[HexNAc]3 √  
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]7[HexNAc]2 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
     
C2 FNGTGPCK [Hex]3[HexNAc]6[Fuc]2  √ 
 ″ [Hex]4 [HexNAc]4 √  
 ″ [Hex]5[HexNAc]4[Fuc]1[NeuNAc]2 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
     
 CNDKKFNGTGPCK [Hex]3 [HexNAc]2  √ 
 ″ [Hex]3 [HexNAc]3 [Fuc]1  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1  √ 
 ″ [Hex]4[HexNAc]2  √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
C2 CNDKKFNGTGPCK [Hex]4 [HexNAc]3 [Fuc]1  √ 
 ″ [Hex]5 [HexNAc]2  √ 
 ″ [Hex]4[HexNAc]2[Fuc]1  √ 
 ″ [Hex]7[HexNAc]2  √ 
 ″ [Hex]8[HexNAc]2  √ 
 ″ [Hex]9[HexNAc]2  √ 
     
 NVSTVQCTHGIKPVVSTQLLL
NGSLAEEEIIIR 
[Hex]3[HexNAc]2  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1  √ 
 ″ [Hex]4[HexNAc]2  √ 
 ″ [Hex]5[HexNAc]2  √ 
 ″ [Hex]6[HexNAc]2  √ 
 ″ [Hex]7[HexNAc]2  √ 
 ″ [Hex]8[HexNAc]2  √ 
 ″ [Hex]9[HexNAc]2  √ 
     
 SENITNNAK Hex]3[HexNAc]5[Fuc]1 √  
 ″ [Hex]4[HexNAc]2  √ 
 ″ [Hex]5 [HexNAc]3 √  
 ″ [Hex]5 [HexNAc]3 [NeuNAc]1 √  
 ″ [Hex]5[HexNAc]2 √  
 ″ [Hex]6[HexNAc]2 √  
 ″ [Hex]6[HexNAc]4 √  
 ″ [Hex]6[HexNAc]5[Fuc]1 √  
 ″ [Hex]7[HexNAc]2 √  
 ″ [Hex]7[HexNAc]4 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
     
C2-V3 TIIVQLNESVEINCTRPNNNTR [Hex]3[HexNAc]2  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1  √ 
 ″ [Hex]4[HexNAc]2  √ 
 ″ [Hex]4[HexNAc]3  √ 
 ″ [Hex]5[HexNAc]2  √ 
 ″ [Hex]7[HexNAc]2  √ 
     
V3-C3 QAHCNISGTK [Hex]4[HexNAc]2  √ 
 ″ [Hex]5[HexNAc]2 √ √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
V3-C3 QAHCNISGTK  [Hex]6 [HexNAc]2  √ 
 ″ [Hex]6[HexNAc]4[NeuNAc]1 √  
 ″ [Hex]7[HexNAc]2  √ 
 ″ [Hex]8[HexNAc]2 √ √ 
 ″ [Hex]9[HexNAc]2  √ 
     
 QAHCNISGTKWNK [Hex]3[HexNAc]8 √  
 ″ [Hex]6[HexNAc]3[Fuc]1[NeuGc]2 √  
     
C3 WNKTLQQVAKK [Hex]7[HexNAc]2 √  
     
 WNK [Hex]9[HexNAc]2 √  
     
 EHFNNK [Hex]3[HexNAc]4[Fuc]1 √  
 ″ [Hex]3[HexNAc]5[Fuc]1 √  
 ″ [Hex]4[HexNAc]4[SO3]1 √  
 ″ [Hex]5[HexNAc]2 √  
 ″ [Hex]5[HexNAc]3[Fuc]1 √  
 ″ [Hex]8[HexNAc]2 √  
 ″ [Hex]9[HexNAc]2 √  
     
 LREHFNNK [Hex]3[HexNAc]2  √ 
 ″ [Hex]3[HexNAc]2[Fuc]1  √ 
 ″ [Hex]3[HexNAc]3  √ 
 ″ [Hex]3 [HexNAc]3 [Fuc]1  √ 
 ″ [Hex]3[HexNAc]4  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1  √ 
 ″ [Hex]3[HexNAc]5  √ 
 ″ [Hex]3[HexNAc]5[Fuc]1  √ 
 ″ [Hex]3[HexNAc]6[Fuc]1  √ 
 ″ [Hex]4[HexNAc]2  √ 
 ″ [Hex]4[HexNAc]2[Fuc]1  √ 
 ″ [Hex]4[HexNAc]3  √ 
 ″ [Hex]4 [HexNAc]3 [Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]4  √ 
 ″ [Hex]4[HexNAc]4[Fuc]1  √ 
 ″ [Hex]4[HexNAc]5  √ 
 ″ [Hex]4[HexNAc]5[Fuc]1  √ 
 ″ [Hex]4[HexNAc]6[Fuc]1  √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
 LREHFNNK [Hex]5[HexNAc]2  √ 
 ″ [Hex]5[HexNAc]3  √ 
 ″ [Hex]5[HexNAc]3[Fuc]1  √ 
 ″ [Hex]5[HexNAc]4  √ 
 ″ [Hex]5[HexNAc]4[Fuc]1  √ 
 ″ [Hex]5[HexNAc]5  √ 
 ″ [Hex]5[HexNAc]5[Fuc]1  √ 
 ″ [Hex]6[HexNAc]2  √ 
 ″ [Hex]6[HexNAc]3  √ 
 ″ [Hex]6[HexNAc]3[Fuc]1  √ 
 ″ [Hex]6[HexNAc]5[Fuc]1  √ 
 ″ [Hex]7[HexNAc]2  √ 
 ″ [Hex]7[HexNAc]3  √ 
 ″ [Hex]7[HexNAc]6  √ 
 ″ [Hex]8[HexNAc]2  √ 
 ″ [Hex]8[HexNAc]3  √ 
 ″ [Hex]9[HexNAc]2  √ 
     
V4 NNNNTNDTITLPCR [Hex]3[HexNAc]2 √ √ 
 ″ [Hex]3[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]4[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]4[NeuNAc]1 √  
 ″ [Hex]3[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]2[Fuc]1 √  
 ″ [Hex]4[HexNAc]3 √ √ 
 ″ [Hex]4[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]5 √  
 ″ [Hex]4[HexNAc]4[Fuc]1  √ 
 ″ [Hex]4[HexNAc]5  √ 
 ″ [Hex]4[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]5[Fuc]1[NeuNAc]2 √  
 ″ [Hex]4[HexNAc]6[Fuc]1[NeuNAc]1 √  
 ″ [Hex]5 [HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3 √ √ 
 ″ [Hex]5[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]4 √ √ 
 ″ [Hex]5[HexNAc]4[Fuc]1 √  
 ″ [Hex]5[HexNAc]5[Fuc]1 √  
 ″ [Hex]6 [HexNAc]2 √ √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF 
V4 NNNNTNDTITLPCR [Hex]6[HexNAc]5[Fuc]1 √  
 ″ [Hex]6[HexNAc]5[Fuc]2  √ 
 ″ [Hex]6[HexNAc]6[Fuc]1 √  
 ″ [Hex]7[HexNAc]2 √ √ 
 ″ [Hex]7[HexNAc]6 √  
 ″ [Hex]7[HexNAc]6[Fuc]1 √  
 ″ [Hex]8[HexNAc]2 √ √ 
 ″ [Hex]9[HexNAc]2 √ √ 
 ″ [Hex]15 [HexNAc]4  √ 
 ″ [Hex]16 [HexNAc]4  √ 
 ″ [Hex]17 [HexNAc]4  √ 
 ″ [Hex]18 [HexNAc]4  √ 
     
C4 SNITGLLLTR [Hex]3[HexNAc]3[Fuc]1 √  
 ″ [Hex]3[HexNAc]4 √  
 ″ [Hex]3[HexNAc]4[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]5 √ √ 
 ″ [Hex]3[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]6[Fuc]1  √ 
 ″ [Hex]4 [HexNAc]3 [Fuc]1 √  
 ″ [Hex]4 [HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]3 √  
 ″ [Hex]4[HexNAc]3[Fuc]1 √  
 ″ [Hex]4[HexNAc]4 √  
 ″ Hex]4 [HexNAc]4 [Fuc]1 
[NeuNAc]1 
√  
 ″ Hex]4 [HexNAc]5  √ 
 ″ [Hex]4[HexNAc]5[Fuc]1[SO3]1 √  
 ″ [Hex]5 [HexNAc]2  √ 
 ″ [Hex]5 [HexNAc]3 √  
 ″ [Hex]5[HexNAc]3[Fuc]1 √  
 ″ [Hex]5[HexNAc]4 √  
 ″ [Hex]6 [HexNAc]2 √ √ 
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]6[HexNAc]4  √ 
 ″ [Hex]6[HexNAc]5 √  
 ″ [Hex]7[HexNAc]2 √ √ 
 ″ [Hex]8[HexNAc]2 √ √ 
 ″ [Hex]9[HexNAc]2 √ √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR  
MALDI-TOF-
TOF  
V5 DGGNNNTNETEIFRPGGGDM
R 
[Hex]3[HexNAc]2  √ 
 ″ [Hex]3[HexNAc]2[Fuc]1  √ 
 ″ [Hex]3[HexNAc]3[Fuc]1  √ 
 ″ [Hex]3[HexNAc]4[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]6[Fuc]1 √ √ 
 ″ [Hex]3[HexNAc]7Fuc]1  √ 
 ″ [Hex]4[HexNAc]2 √ √ 
 ″ [Hex]4[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]4  √ 
 ″ [Hex]4[HexNAc]4[Fuc]1     √ 
 ″ [Hex]4[HexNAc]5 √ √ 
 ″ [Hex]4[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]4[HexNAc]5[Fuc]1[NeuNAc]1 √  
 ″ [Hex]4[HexNAc]6[Fuc]1  √ 
 ″ [Hex]4[HexNAc]6[Fuc]1[NeuNAc]1 √  
 ″ [Hex]5[HexNAc]2 √ √ 
 ″ [Hex]5[HexNAc]3[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]4[Fuc]1  √ 
 ″ [Hex]5[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]5[HexNAc]5[Fuc]1[NeuNAc]1 √  
 ″ [Hex]5[HexNAc]6[Fuc]1  √ 
 ″ [Hex]6 [HexNAc]2 √ √ 
 ″ [Hex]6[HexNAc]3[Fuc]1 √  
 ″ [Hex]6[HexNAc]3[NeuNAc]1 √  
 ″ [Hex]6[HexNAc]4[NeuNAc]1 √  
 ″ [Hex]6[HexNAc]5[Fuc]1 √ √ 
 ″ [Hex]6[HexNAc]5[Fuc]1[NeuNAc]1 √  
 ″ [Hex]6[HexNAc]7[Fuc]2  √ 
 ″ [Hex]6[HexNAc]8[Fuc]2  √ 
 ″ [Hex]6[HexNAc]9[Fuc]2  √ 
 ″ [Hex]6[HexNAc]10[Fuc]2  √ 
 ″ [Hex]6[HexNAc]11[Fuc]2  √ 
 ″ [Hex]6[HexNAc]12[Fuc]2  √ 
 ″ [Hex]7[HexNAc]2 √ √ 
 ″ [Hex]7[HexNAc]7[Fuc]2  √ 
 ″ [Hex]7[HexNAc]9[Fuc]2  √ 
 ″ [Hex]7[HexNAc]10[Fuc]2  √ 
 ″ [Hex]7[HexNAc]11[Fuc]2  √ 
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Env 
Domain 
Peptide Sequence Carbohydrate Composition LC/ESI-
FTICR 
MALDI-TOF-
TOF  
V5 DGGNNNTNETEIFRPGGGDM
R  
[Hex]8[HexNAc]2  √ 
 ″ [Hex]8[HexNAc]4  √ 
 ″ [Hex]8[HexNAc]6[Fuc]2  √ 
 ″ [Hex]8[HexNAc]7[Fuc]2  √ 
 ″ [Hex]8[HexNAc]8[Fuc]2  √ 
 ″ [Hex]9[HexNAc]2  √ 
 ″ [Hex]9[HexNAc]4  √ 
 ″ [Hex]10[HexNAc]4  √ 
 ″ [Hex]11[HexNAc]4  √ 
 ″ [Hex]12[HexNAc]4  √ 
 ″ [Hex]13[HexNAc]4  √ 
 ″ [Hex]13[HexNAc]5  √ 
 ″ [Hex]13[HexNAc]6  √ 
     
TM EINNYTDIIYSLIEESQNQQEK Non-glycosylated √  
     
 DQQLEIWDNMTWMEWER Non-glycosylated  √ 
     
 DQQLEIWDNMTWMEWER Non-glycosylated  √ 
     
 
                    √ - Indicate that the glycoform in question was detected   
                    TM – Transmembrane  
                    Hex – Hexose; HexNAc – N-acetylglucosamine; Fuc – Fucose 
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4.5 Significance of analyzing CON-Sgp140∆CFI  
 The HIV-1 virus is highly pathogenic, causing one of the deadliest 
diseases known in human history; therefore, developing a vaccine against 
this virus is an urgent global priority.  So far, considerable efforts have been 
made towards designing an efficacious HIV vaccine. For a vaccine to be 
considered as effective, it would have to prevent HIV infection in the 
vaccinated individuals through eliciting an effective immune response or 
limiting HIV replication rates, thus delaying/preventing HIV progression to 
AIDS in the infected individuals. Unfortunately, attempts to design such a 
vaccine or immunogen have been largely unsuccessful.  
One of the major hurdles for developing an effective HIV vaccine is 
the high level of genetic diversity resulting from its rapid replication and 
mutational rates. This results in high variability in amino acid sequences of 
the same HIV-1 group. For instance, HIV-1 main (M) group is the major 
cause of the HIV pandemic. Within this group there are nine major subtypes 
or clades, which include A to D, F to H, J, and K. Sequence variability is 
known to occur between different subtypes and within the same subtype. As 
a result, it is unrealistic to develop a vaccine based on only one subtype. 
However, most of the current strategies to develop an HIV vaccine have 
failed to address the genetic variability of HIV-1 strains. Recently, a new 
approach was developed that addresses the genetic variability by designing 
immunogens that are based on “centralized” (ancestral or consensus) HIV 
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sequences thereby minimizing the genetic gap between different HIV strains. 
Such an immunogen would be a better representative of contemporary 
viruses and is expected to elicit neutralizing antibodies against a broader 
spectrum of viral strains. So far, only a few immunogens have been 
developed using this approach. One of the most successful immunogens in 
eliciting neutralizing antibody response from various subtypes of HIV-1 group 
M is CON-Sgp140∆CFI, making this immunogen a potential candidate for 
HIV vaccine.  
Although designing an immunogen with “centralized” sequence is a 
great advancement towards developing an effective vaccine, it is critically 
important to analyze the extensive glycosylation pattern on the surface of the 
immunogen, since it is known to be the key defense mechanism for the virus 
against immune attack. As a result, to successfully design an efficacious HIV 
vaccine, one of the initial fundamental steps is to map and profile 
glycosylation patterns present in HIV envelope proteins and correlate this 
glycosylation information to their immunological properties. To this end, we 
have developed mass spectrometric methods to characterize the CON-S 
gp140∆CFI glycosylation pattern. This information will facilitate development 
of an HIV vaccine that not only optimizes on the peptide sequence but also 
on the glycan moieties. 
4.5.1 CON-S consensus gene design 
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CON-S, a synthetic group M consensus env gene, was constructed by 
aligning the consensus env sequences of group M subtypes A to D, F and G 
from the 2001 HIV sequence database as described in (http://hiv-
web.lanl.gov/content/hiv-db/CONSENSUS/M_GROUP/Consensus.html). The 
alignment only contained full-length proteins and one sequence from each 
individual.  Besides the hypervariable loops, this consensus has the same 
regions as a model of the ancestral sequence of the group M that is based 
on maximum probability phylogenies.37 The hypervariable loop regions (V1, 
V2, V4, and V5) in the env gene evolve by rapid insertion and deletion, 
whereas the V3 region mainly evolves by point mutation with minimal 
insertions and deletions.  These regions were designed by hand alignments 
that initially brought potential N-linked glycosylation sites and cysteines into 
alignment before bringing the repeated sequence motifs within loops into 
alignment. The V3 hypervariable region was aligned and treated in the same 
manner as the conserved (C1 to C4) Env regions. Most of the positions of 
each subtype maintained the same amino acids producing a consensus of 
consensuses. The resulting consensus contained hypervariable loop 
sequences of shorter range of lengths than found among natural strains. This 
was desirable because the shorter hypervariable loops are more likely to 
expose conserved epitopes that can easily be accessed by neutralizing 
antibodies.  
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4.5.2 Expression of recombinant HIV-envelopes 
A detailed description of how CON-S was expressed can be found in 
literature.29,37 Briefly, the gene for CON-S env was generated by converting 
its protein sequence into a nucleotide sequence. This was done by utilizing 
the codon usage of highly expressed human housekeeping genes and de 
novo synthesized. HIV-1gp140 Envs with the deletion of the cleavage (C) 
site, fusion (F), and immunodominant (I) region in gp41 hence the name 
gp140CFI. CON-S gp140ΔCFI was generated by PCR by introducing a stop 
codon before the spanning domain (YIKIFIMIVGGLIGLRIVFAVL SIVN). 
Recombinant vaccinia virus (rVV) expressing CON-Sgp140ΔCFI were 
generated and confirmed by PCR and nucleotide analysis after transfection 
into 293T cells. Recombinant CON-Sgp140ΔCFI glycoprotein was purified 
from supernatants of 293T cell cultures using Galanthus nivalis lectin-
agarose (Vector Labs, Burlingame, CA) column chromatography and stored 
at –70oC until use. 
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CHAPTER 5 
 
Conclusion and Future Directions 
 
The work described herein focused on developing mass spectrometric 
methods to characterize glycans in different glycoproteins in a glycosylation 
site-specific fashion. This approach is highly efficient and allows structural 
elucidation of both the glycans and their attachment site in a single-MS 
experiment. A complete characterization of glycans from two important 
classes of glycoproteins, pituitary glycoproteins and HIV envelope 
glycoproteins, was performed in a glycosylation site-specific fashion.  
The glycans present in pituitary glycoproteins are known to contain 
unusually high content of terminal residues such as sulfate groups and sialic 
acid. However, the precise degree of sulfation or sialylation in different 
glycosylation sites in these glycoproteins and the roles that these residues 
play are still not well understood. This is mainly due to the acidity and lability 
of these groups creating a big analytical challenge that has greatly influenced 
the analysis of these species.  Consequently, developing efficient and 
sensitive analytical techniques that are capable of identifying and 
characterizing negatively charged glycans in a glycosylation site-specific 
manner are highly desirable, in order to facilitate the understanding of their 
biological significance. 
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Different mass spectrometric methodologies for characterizing glycans 
containing these terminal residues in a glycosylation site-specific manner 
were developed. These methods were successfully applied in characterizing 
all the three pituitary hormones (LH, FSH and FSH). The results provided 
herein are specifically from the analysis of eFSH and eTSH. To characterize 
the glycan structures on these glycoproteins, a non-specific enzyme was 
utilized to generate small glycopeptides that are easier to separate. However, 
analysis of these glycopeptides can be challenging since it involves 
simultaneous analysis of two unknowns; the peptide and the glycan portions.  
To facilitate identification of the peptide portion, a web-based tool was 
developed. This tool, known as GlycoPep ID, identifies the peptide portion of 
negatively charged glycopeptides generated from a non-specific enzyme 
(proteinase K) by predicting the characteristic product ion observed in (-
)MS/MS data of these glycopeptides that corresponds to the peptide portion.  
The versatility of this method was demonstrated by identifying the peptide 
moieties of glycopeptides from two different glycoprotein hormones, FSH and 
TSH, that were exclusively sialylated or sulfated, or were both sialylated and 
sulfated. A total of 27 peptide moieties were correctly identified by GlycoPep 
ID and validated using data from a combination of Edman chemistry and high 
resolution FTICR-MS analysis.  This technique represents an important 
advance in glycosylation profiling because it solves one of the most difficult 
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problems of using a non-specific enzyme in glycopeptide analysis: 
Determining where the enzyme cleaved the protein.    
While (-) MS/MS data was useful in identifying the peptide moiety, it 
provided very minimal glycan structural information, and the amount of 
information in the spectra vary, depending on the number of SO3 groups and 
the charge state of the ion. To overcome this challenge, an ion-pairing 
approach was developed. This approach utilizes a basic tripeptide to non-
covalently interacting with the sulfate group of the sulfated glycopeptide 
thereby stabilizing it, promoting dissociation pathways that provide more 
informative product ions. The resulting ion-pair complexes are analyzed 
using (+) MS/MS to provide structural information on the glycan portion of 
these glycopeptides. All the sulfated glycopeptides from eTSH were 
characterized using this approach. The results clearly demonstrated the 
efficacy of using ion-pairing MS/MS to fully characterize sulfated 
glycopeptides in a glycosylation site-specific fashion, an approach that is 
complementary and in most cases superior to (-)MS/MS analysis. The ion-
pairing approach provided a wealth of structural information about the glycan 
portion in addition to being useful for identifying the peptide moiety.  The 
information obtained from MS/MS of the ion-pair complexes was independent 
of the number of SO3 groups present or the charge state of the ion and can 
be used to determine the branching, sequence, and type of N-glycan present 
in a sulfated glycopeptide.   
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Although mass spectrometry is widely used for glycoprotein analysis, 
so far there is no consensus as to which mass spectrometric approach is 
most suitable or would provide the most glycosylation information with a high 
degree of confidence. As a result, an investigation was conducted using two 
high-resolution MS techniques; MALDI-TOF/TOF and LC/ESI-FTICR MS, to 
provide glycosylation information of a potential vaccine candidate for the HIV 
virus, CON-S gp140∆CFI. CID experiments acquired in both instruments 
indicated that ESI-MS/MS in a linear ion trap provided the best confidence 
level for confirming the glycan moiety while MS/MS on a MALDI-TOF/TOF 
provided a higher confidence level for confirming the peptide portion of the 
same glycopeptide. When used together, the two instruments provided 
glycopeptide composition assignments of very high confidence level. In terms 
of glycosylation data, different populations of N-linked glycans comprising of 
a wide-range of high-mannose, hybrid, and complex types N-linked glycans, 
were identified and characterized in a glycosylation site-specific manner.  
Overall, the high-mannose glycans were identified as the most abundant 
glycoforms from both MS techniques. Approximately 350 glycopeptide 
compositions were identified, when data from the two techniques were 
combined. The information presented in this study provides other 
researchers with useful insights about what MS methods are most 
appropriate for glycopeptide analysis, and how those methods can be used 
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synergistically to provide optimal glycosylation coverage and high confidence 
assignments. 
Future Directions 
Unlike the proteomics and glycomics fields where methods of analysis 
are well established, in the glycoproteomics field, methods of analysis are 
still under development. The work presented herein makes a significant 
contribution in advancing this field by solving several problems that have 
been major hurdles in glycoprotein analysis. These methods can be applied 
in future studies in fully characterizing HIV envelope proteins. Although a 
characterization of glycans in an HIV envelope protein was described herein, 
the mass spectral data analyzed from this protein mainly focused on the 
positive ion mode data. However, analysis in the positive ion mode mainly 
favors neutral species while the signal for negatively charged species is 
suppressed by the strongly ionizing neutral species. This is evident from the 
data reported, which indicated that less than 10% of all the glycans present 
in this HIV envelope protein are negatively charged. Moreover, previous 
studies have suggested that approximately 40% of the glycans found on HIV 
env proteins contain negatively charged residues. This implies that the 350 
glycan compositions characterized in our studies only represent 60% of the 
total glycans present while the rest remain to be characterized. Since the 
presence of negatively charged species can act as points of interactions or 
as specific recognition markers for receptor binding, characterizing glycans 
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capped with these residues in HIV envelope proteins is of great importance. 
The ion pairing approach could be used to stabilize the sulfate group, when 
present, to facilitate structural analysis of these glycans; whereas GlycoPep 
ID can be used to simplify mass spectral data analysis.  
In addition, since the envelope proteins in the HIV virus are known to 
evolve rapidly during infection and HIV disease progression by changing the 
glycan position, number, and structures, resulting in new virus strains that 
successfully escape any immune attack, a thorough investigation of 
glycosylation on different HIV envelope proteins originating from the same or 
different strains is required. Thus future work will include such a study that 
would focus on identifying the conserved glycosylation sites in HIV proteins 
which can eventually be targeted during HIV vaccine development. Since the 
glycosylation process is host cell dependent, a careful evaluation should be 
performed to determine the relative consistency of glycosylation patterns 
found in different mammalian cells that are typically used to propagate HIV 
viruses. Once the overall glycosylation patterns are defined, the mammalian 
cell line containing the most conserved glycosylation pattern would be 
selected for vaccine development purposes. Further studies will be 
performed to map glycosylation patterns of different HIV envelope proteins 
expressed in the selected cell line to identify the conserved glycosylation 
sites or glycosylation sites that are unutilized or contain small glycans that 
are easily accessible to neutralizing antibodies. The glycosylation information 
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obtained therewith, when correlated with the immunological response of 
these proteins, will greatly facilitate development of an effective HIV vaccine.   
In addition, future studies would also focus on facilitating development 
of new types of HIV vaccines. Several studies have reported striking 
disparities between the glycans of HIV-infected and healthy cells. For 
example, the presence of dense high mannose glycans structures on gp120 
is a unique feature of infected cells that is not typical of healthy cells. The 
feasibility of exploiting such unique features to develop an HIV vaccine was 
demonstrated by the discovery of 2G12, one of the broadly neutralizing 
human antibodies to HIV. Another way to exploit these distinct glycan 
features would be to develop a glycopeptide-based HIV vaccine. Since 
glycans are known to be poor immunogens, the invention of this type of 
vaccine will be able to take advantage of the unique features of glycans and 
also target the conserved peptide moiety where the glycans are attached. 
This will not only lead to a vaccine that has better immunogenecity than the 
glycan-based vaccine, but may also unravel new epitopes that could 
potentially be used as targets for neutralizing antibodies. However, the 
progress of these studies will not only require a fundamental knowledge of 
the glycan structures on HIV envelope glycoproteins but also their specific 
locations on the protein. Consequently, the developed mass spectrometric 
methodologies presented herein could be used facilitate such studies. 
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